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CHAPTER I
RESEARCH PROBLEM
Introduction to Topic
Elevated serum uric acid concentrations, or hyperuricemia, can be caused by
impaired renal uric acid excretion or enhanced renal tubular uric acid reabsorption (Voel
and Voet 1990). Hyperuricemia is associated with the incidence of obesity, diabetes
mellitus, hyperlipidemia, hypertension, and atherosclerosis (Wyngaarden and Kelley 1976).
Several studies have found hyperuricemia to independently predict ischemic heart disease
and total mortality (Freedman et aI. 1995).
Facchini and associates (1991) suggested that insulin resistance decreases renal
uric acid clearance which increases serum uric acid concentrations. Hyperuricemia is also
related to certain stages of glucose intolerance. Herman and Goldbourt (1982) reported
that serum uric acid concentrations were elevated in Impaired Glucose Tolerance (IGT),
then began to fall and continued to decrease with the manifestation and progression of
Non-Insulin Dependent Diabetes Mellitus (NIDDM).
Insulin seems to inhibit uric acid secretion or enhance uric acid reabsorption at the
renal tubular level (Galvan et aI. 1995). In addition, glucose competitively inhibits uric
acid reabsorption in the proximal tubules of the kidneys in hyperglycemic and glycosuric
patients (Herman et aI. 1976).
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Hyperinsulinemia is a state ofabnormally elevated insulin levels in the blood
(Zimmet 1993). Hyperinsulinemia is most commonly associated with the insulin resistant
state, a fundamental aspect ofIGT (perry et at. 1995). Hyperinsulinemia does not
continue throughout the natural progression ofNIDDM, though. Once overt diabetes has
developed and fasting glucose levels exceed 120 mgldL, the pancreas decompensates by
reducing the secretion of insulin in response to the continued hyperglycemia (DeFronzo
1988). Insulin resistance. characterized by hyperinsulinemia, is now thought to be the
underlying metabolic abnormality connecting obesity, hypertension, hyperlipidemia, and
glucose intolerance (Vuorinen-Markkola and Yki-Jarvinen 1994).
Chromium is a trace element that appears to increase the activity or efficiency of
insulin (Anderson.et al. 1991) which improves glucose tolerance. Anderson and
colleagues (1991) found that consuming diets low in chromium produced detrimental
effects on glucose tolerance, insulin, and glucagon levels in hyperglycemic subjects. Doisy
and associates (1976) reported IGT to be one ofthe first physiological signs ofchromium
deficiency.
In humans, chromium deficiency has resulted in glucose and lipid abnormalities,
neuropathy, and encephalopathy (Anderson 1987). In animals deficient in chromium,
impaired growth, decreased longevity, aortic plaques, comeallesions, and decreased
fertility have all been observed (Anderson 1987). In our laboratory, deficient chromium
nutriture resulted in elevated serum uric acid concentrations (Stoecker et a1. 1996).
Chromium deficiency has been hypothesized as a significant risk factor for cardiovascular
disease (Schroeder 1968). Because serum lipid levels are affected by glucose tolerance
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and insulin sensitivity, adequate chromium nutriture may help maintain normal serum lipids
(Riales and Albrink 198I).
Three patients dependent upon total parenteral nutrition for long periods of time
were documented as having chromium deficiency symptoms including weight loss,
peripheral neuropathy, glucose intolerance, and an increased caloric requirement for
weight maintenance (Brown et al. 1986, Freund et al. 1979, Jeejeebhoy et al. 1977).
Chromium supplementation generally reversed these observed deficiency symptoms
(Anderson 1987, Jeejeebhoy et al. 1977), but the effects of supplemental chromium
depend on the degree ofdeficiency (Mertz et aI. 1965) and the degree ofglucose
il1tolerance (Anderson et al. 1991). Metabolic stress may intensifY chromium deficiency
symptoms and increase its essentiality in selected subjects (Nielsen 1988, Stoecker 1995).
Anderson and collegues (1991) found that more than 9QO.Io ofthe self-selected diets
in the United States provided less than 50 /-Lg of chromium, the minimum Estimated Safe
and Adequate Daily Dietary Intake (ESADDI) suggested by the National Academy of
Sciences (Anderson et al. 1991, Food and Nutrition Board 1989).
Copper is a mineral that supports the integrity of the cardiovascular system
tlrrough elastin and collagen biosynthesis (Davis and Mertz 1987). Many studies have also
shown strong effects of cOpPer on the metabolism of lipids and cholesterol (Davis and
Mertz 1987). Copper has also been shown to affect immune function, the regulation of
glucose metabolism, and play many other physiological roles in the body (Davis and Mertz
1987).
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Copper deficiency results in anemia, alterations in iron metabolism, skeletal
changes, hair and skin changes, neurologic disease and cardiovascular disorders (O'Dell
1990). Klevay (1980) observed elevated serum uric acid concentrations in response to
copper deficiency. Investigators have documented an impairment ofglucose metabolism
in copper deficient animals and humans (Davis and Mertz 1987). Fields and associates
(1983b) injected both insulin and copper separately into streptozotocin-induced diabetic
..
rats to study the affects ofcopper on glucose utilization. Copper alone did significantly
improve IGT, as did insulin; but when insulin and copper were injected together, a stable
complex was formed which synergistically increased peripheral insulin binding and
decreased insulin degradation (Fields et aI. 1983b). In another study, KJevay and
.. ~ " t
associates (1986) found IGT to be the chiefmanifestation ofcopper deficiency in two
men. Copper sulfate supplementation returned the glucose tolerance to nonnal. Davis
and Mertz (1987) reported that true copper deficiency results in an elevation of serum
cholesterol. Allen and Klevay (1980) reported a significant increase of low density
lipoprotein cholesterol (LDL), total cholesterol, and triglyceride levels and a significant
decrease in high density lipoprotein cholesterol (IIDL) in serum of copper deficient rats.
Pennington and colleagues (1986) reported that diets of infants, children,
adolescents, adult men and women, and elderly men and women in the United States were
all low in copper when compared to their respective ESADDI recommendations.
The BHE/cdb rat is an excellent animal model for studying IGT. This strain is
bred to reliably manifest age-related abnormal glucose tolerance and glomerulosclerosis
without the usual complications ofobesity and hydronephrosis (Berdanier 1991). By 300
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days ofage, 75% of this strain develops abnormal glucose tolerance, fasting lipemia,
premature renal disease, and a fatty liver (Berdanier 1991). With the presence ofIGT, the
BHFlcdb rat should exhibit hyperinsulinemia and hyperuricemia.
Significance of the Problem
Hyperuricemia and hyperinsulinemia are present in many related physiological and
metabolic abnormalities often associated with cardiovascular disease and diabetes mellitus
(Facchini et al. 1991, Zimmet 1993). Chromium and copper dietary intakes were found to
be low in self-selected diets in the United States (Anderson et al. 1991, Pennington et aI.
1986).
Chromium has the potential to prevent or delay the deterioration of glucose
tolerance that ultimately develops into NIDDM (Mertz 1993) by potentiating the action of
insulin. If self-selected diets are too low in chromium, this benefit will not be observed.
In addition, chromium 'COuld help lower the resultant hyperinsulinemia associated with the
insulin resistant state if chromium potentiates the action of insulin on glucose uptake by
peripheral tissues. Lower insulin levels in the blood would also decrease the enhanced
tubular reabsorption ofuric acid associated with hyperinsulinemia (Galvan et al. 1995).
Lower serum levels ofboth uric acid and insulin could decrease risk of cardiovascular
disease.
Klevay (1980) .suggested that a metabolic imbalance in regard to zinc and copper is
a major factor in the etiology ofischemic heart disease. In one study, copper deficient rats
exhibited hyperuricemia, hypercholesterolemia and increased mortality (Klevay 1980). If
copper nutriture is adequate, the risk of cardiovascular disease from hyperuricemia and
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dyslipidemia could decrease. Copper deficiency adversely affects glucose metabolism
which is fundamental to the metabolic abnormalities ofdiabetes (Davis and Mertz 1987).
Copper and insulin together increased peripheral insulin binding (Fields et al. 1983b)
which would lessen hyperinsulinemia. Sufficient copper, then, should improve glucose
tolerance which could delay the onset ofNIDDM. The interaction between deficient
copper and chromium should even further exacerbate the expected metabolic changes
leading to increased risk of cardiovascular disease and NIDDM.
Objectives
The objectives ofthis research were to investigate the effects of chromium and
copper on serum uric acid concentrations and other physiological parameters in the
BHE/cdb rat, an animal model for abnonnal glucose tolerance.
The objectives of this study were to:
1. Detennine the effect ofdietary chromium on selected factors related to
cardiovascular disease risk in the BHE/cdb rat.
2. Detennine the effect ofdietary copper on selected factors related to
cardiovascular disease risk in the BHE/cdb rat.
3. Detennine the interactive effect of dietary chromium and copper on
selected factors related to cardiovascular disease risk in the BHE/cdb rat.
Null Hypotheses
The following hypotheses were developed for this study:
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I. There will be no statistically significant effect of dietary chromium on
selected factors related to cardiovascular disease risk in the BHE/cdb rat.
2. There will be no statistically significant effect ofdietary copper on selected
factors related to cardiovascular disease risk in the BHE/cdb rat.
3. There will be no statistically significant interactions between dietary
chromium and copper effecting selected factors related to cardiovascular
disease risk in the BHE/cdb rat.
Limitations
This study is subject to several limitations which must be identified. Data from
animal studies cannot be extrapolated directly to humans. This particular animal study
evaluated only the effects ofadequate and inadequate intakes ofchromium and copper;
thus, supplementation effects ofthese minerals were not studied. In addition, chromium
research is subject to particular environmental contamination issues which increase the
difficulty ofestablishing a true mineral deficiency.
Fonnat of Thesis
The tables and bibliographic citations in this thesis follow the guide for authors for
the Journal ofNutrition.
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CHAPTER II
REVIEW OF THE LITERATURE
This chapter includes a literature review of hyperuricemia, hyperinsulinemia,
chromium, and copper and their roles in glucose and lipid metabolism. A discussion of the
BHE/cdb rat as an animal model for Impaired Glucose Tolerance (IGT) is also included.
Hyperuricemia
Uric acid is a circulating end product ofpurine metabolism (Frohlich 1993).
Hyperuricemia is associated with impaired uric acid excretion, and thus, elevated serum
uric acid concentrations (Voet & Voet 1990)~ however, not all hyperuricemia indicates the
condition ofgout.
Elevated serum uric acid concentrations are encountered regularly in situations
such as hypertension, reduced high density lipoprotein (HDL) cholesterol,
hyperinsulinemia, reduced physical activity, increased body mass index, and increased
alcohol intake. These factors as a group are commonly referred to as the Obesity-Insulin
Resistance Syndrome (Lee et aI. 1995). This syndrome of related physiological
abnormalities is often found in coronary heart disease patients (Facchini et al. 1991).
Several of these conditions are also characteristic of non-insulin dependent diabetes
mellitus (NIDDM) (Zimmet 1993).
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Hyperuricemia, or elevated serum uric acid concentration, is geneticaUy
determined, but also influenced by many environmental factors (Tuomilehto et a1. 1988).
Serum uric acid concentrations ~ 7.0 mg/too mL (0.42 mmollL) in adult males and ~ 6.0
mg/l00 mL (0.36 mmoVL) in adult females generally indicate hyperuricemia (Wyngaarden
and Kelley 1976).
Incidence
The prevalence ofhyperuricemia seems to follow the incidence of obesity, diabetes
mellitus, hyperlipidemia, hypertension, and atherosclerosis and coronary heart disease
(Wyngaarden and Kelley 1976). In the Normative Aging Study involving middle to older
age men, serum uric acid levels were positively and significantly associated with an
increase in body mass index, abdomen to hip ratio, post-carbohydrate insulin level, and
alcohol intake (Lee et a1. 1995). Serum uric acid was negatively related to age and
physical activity level, while total body adiposity and abdomen to hip ratio were strongly
related to high serum uric acid after all other factors were removed (Lee et al. 1995).
In a study ofhealthy individuals with no history ofdisease, insulin resistance and
serum uric acid concentrations were significantly related (Facchini et al. 1991). This
positive relationship remained significant when age, sex, body mass index, and abdominal
obesity were considered. As individuals became more insulin resistant, renal uric acid
c1eaFance decreased and serum uric acid concentrations increased. This study suggested
that insulin resistance decreases renal uric acid clearance, which subsequently increases
serum uric acid concentrations (Facchini et a1. 199]).
9
A recent study ofpregnant women by Kaaja et aI. (1995) also supports a
connection between hypertension and the incidence of hyperuricemia. This study found
elevated serum uric acid concentrations, 18% lower HDL cholesterol, 65% higher
triglyceride levels and 100% higher insulin levels in hypertensive pregnant women as
compared to normotensive pregnant controls (Kaaja et aI. 1995).
Fructose seems to have a hyperuricemic effect in certain individuals. Henry et a1.
(1991) suggest that those individuals who are predisposed to this hyperuricemia include
hyperinsulinemic men. Stirpe and associates (1970) summarized reports offructose
administration as causing serum uric acid elevations in both normal children and children
with congenital fructose intolerance. On the other hand, intravenous fructose had no
effect on serum uric acid concentrations in young men, but an obvious and prolonged rise
in serum uric acid resulted from fructo.se admioi~tr~tion tQ patients with gout and children
ofpatients with gout. 1
Hyperuricemia not only accompanies different risk factors for cardiovascular
disease, but seems to only associate with certain stages ofglucose intolerance. Modan et
al. (1987) found elevated serum uric acid levels only in the presence of hyperinsulinemia in
1016 Jewish men and women participating in the Israel Study of Glucose Intolerance,
Obesity and Hypertension. The elevated serum uric acid concentrations were found in
normal glucose tolerant, impaired glucose tolerant, and newly diagnosed diabetic patients.
As diabetes progressed, though, serum uric acid levels decreased significantly (Modan et
aI. 1987). A similar study also done in Israel with 10,000 men confirmed these findings
(Herman et &1. 1976). Subjects who did not have symptoms of diabetes at first, but
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developed symptoms in the next three to five years were tenned "prediabetic." These
prediabetics exhibited the highest serum uric acid ooncentrations. The abnormal glucose
tolerant had intermediate, but still higher than normal serum uric acid conoentrations while
the subjects diagnosed with Type II diabetes exhibited the lowest serum uric acid levels.
This trend seemed to continue with the development ofthe disease (Hennan et al. 1976).
Herman and Goldbourt again reported in 1982 that serum uric acid concentrations were
high before the onset ofdiabetes, began to fall, and continued to decrease with the
increasing duration ofthe disease. . {. ,(
In the biracial population ofFiji, both the indigenous Melanesians and the
immigrated Asians exhibited first elevated and later decreased serum uric acid
concentrations as glucose intolerance and diabetes progressed despite differences in the
diagnostic criteria for these two disease conditions (Tuomilehto et al. 1988). Using the
World Health Organization classifications for IGT and diabetes mellitus (WHO 1980), the
highest plasma uric acid levels were found in men with impaired glucose tolerance in both
racial groups. Type II diabetic men had the lowest plasma uric acid concentrations in both
populations. Hyperuricemia occurred in 27% of the Melanesian men and women and 22%
in Asian men and 11% in Asian women (Tuomilehto et a1. 1988).
Pathophysiology
The exact mechanism for the development of elevated serum uric acid
concentrations is not known, although many suggestions have been made. Hyperuricemia
can be caused by either an overproduction of uric acid due to an increased breakdown of
nucleic acids through purine metabolism or by decreased excretion due to increased
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retention ofuric acid in the kidneys indicative ofkidney disease (Tuomjlehto etal. 1988).
Both possibilities will be reviewed here.
Hennan and Goldbourt (1982) recognized that renal uric acid excretion is
enhanced by hyperglycemia. They postulated that hyperuricemia could be due to an error
in carbohydrate metabolism. An interference in glycolysis would divert metabolic flow
through the hexose monophosphate pathway which would result in uric acid production.
Additionally, an increase in fatty acid exidation would inhibit pyruvate dehydrogenase and
phosphofructokinase resulting in uric acid formation (Herman and Goldbourt 1982).
In a study of 14 males, insulin resistance 'and serum triglyceride levels were
positively and significantly correlated with serum uric acid, independent ofobesity, age,
and sex factors (Vuorinen-Markkola and Yki-Jarvinen 1994). These researchers proposed
a mechanism to explain this connection. Elevated serum uric acid may originate from
increased turnover and degradation of AMP, ADP, or ATP, or dinucleotides such as
NADP or NADPH, since uric acid is a purine base. In patients with hypertriglyceridemia,
lipolysis is enhanced and resistant to the action of insulin. The proportion offree fatty
acids (FFA) released from triglycerides during lipolysis accelerates ATP turnover which
may then increase serum uric acid (Vuorinen-Markkola and Yki-Jarvinen 1994).
Israel et al. (1983) postulated that hyperuricemia was induced by sucrose or
fructose. Fructose is rapidly phosphorylated resulting in sudden decreases in hepatic ATP
and serum inorganic phosphorous concentrations which causes a breakdown ofpreformed
nuc1eotides to uric acid (Henry et aI. 1991). An increase in activity in the hexose
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monophosphate shunt could also result in the production of the substrate necessary for
purine synthesis (Israel et al. 1983).
Kock et a1. (1994) reported that during ischemia, there is a calcium dependent
enzymatic degradation ofxanthine oxidoreductase from the NAD+ consuming
dehydrogenase form to an oxidase form, ':Vhich directly utilizes molecular oxygen as an
electron acceptor in the oxidation ofhypoxanthine via xanthine to uric acid. The xanthine
concentrations measured in serum significantly increased in samples of myocardial
infarction patients. Therefore, the metabolic activity ofxanthine oxidoreductase in
myocardial infarction was supported by this research study.
In 1980" Klevay found that copper deficiency demonstrated by
hypercholesterolemia in male rats did incr~e the concentration of serum uric acid.
Klevay (1980) discussed two possible mechanisms for hyperuricemia in the presence of
copper deficiency. He ,suggested that perhaps when copper nutriture is adequate, xanthine
oxidase, which contains molybdenum, is partially inhibited, thus lowering the level ofuric
acid produced. Molybdenum is an antagonist ofcopper and has been shown to
hyperactivate xanthine oxidase and the production of uric acid when ingested in excessive
amounts (Davis and Mertz 1987). Klevay (1980) also suggested that copper deficiency
inhibits the action ofuricase, an enzyme which contains copper in pigs.
In 1973, Diamond and Paolino published a report suggesting for the first time that
renal tubular reabsorption ofuric acid occurs,in part at a site in the renal tubule distal to
the site for uric acid secretion. Thus, a portion of the secreted uric acid is reabsorbed at
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this site. Their work is now commonly accepted (Tietz 1994). This suggestion explained,
in part, the renal handling mechanisms of uric acid.
Tietz (1994) describes four steps in the renal handling ofuric acid. First, ,the
kidney filters virtually all of the plasma uric acid entering the glomerulus. Secondly, about
98% to 100% of the filtered uric acid is reabsorbed in the proximal convoluted tubule.
Next, 5 to 100A. is secreted in the distal portion of the proximal tubuli. Finally, a further
reabsorption of secreted uric acid takes plact at the distal post-secretory site described
above.
Insulin increases proximal sodium reabsorption. Researchers in Italy suggested
that in conditions ofhyperinsulinemia where more sodium is reabsorbed at sites of the
nephron proximal to the distal tubule, more uric acid could be reabsorbed as well
(Cappuccio et aI. 1993). An activation ofa sodium-hydrogen exchange in the proximal
renal tubular cells would promote a increase in sodium reabsorption, and also an increase
in anion reabsorption, including uric acid. This would lead to elevated serum uric acid
concentrations, or hyperuricemia, and reduced urinary uric acid levels.
Insulin inhibits uric acid secretion or enhances uric acid reabsorption at the tubular
level (Galvan et aI. 1995). Acute hyperinsulinemia also decreases the excretion and
clearance rate of sodium. Galvan et aI. (1995) postulated that hyperinsulinemia could
exert a constant antinatriuretic pressure which would lead to high blood pressure and
reduce uric acid excretion leading to hyperuricemia.
Serum uric acid levels are frequently elevated in patients with hypertension or
ischemic heart disease (Freedman et aI. 1995). Freedman and colleagues suggested that
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uric acid is involved in platelet adhesiveness and aggregation, or it may be secondary to
preexisting disease, which they felt could indicate early renal involvement with
cardiovascular disease. Newland (1975) also indicated that hyperuricemia might playa
role in heart disease through thrombosis. Newland (1975) stated that hyperuricemia
increases the stability ofplatelet aggregates, the initial event in thrombosis, and thus would
increase the incidence ofthrombosis and arterial disease in byperuricemic individuals.
Glucose seems to competitively inhibit uric acid reabsorption in the proximal
tubules of the kidney in patients exhibiting hyperglycemia and glycosuria (Hennan et al.
1976). This decreased uric acid reabsorption would eventually result in increased uric acid
excretion and decreased serum uric acid concentrations. This mechanism could help
explain the decreasing serum uric acid levels seen in the progression ofuncontroUed
diabetes (Herman et al. 1976).
Tuomilehto et al. (1988) found plasma creatinine to be the strongest predictor of
plasma uric acid concentrations. This finding suggests a strong renal involvement in the
balance of plasma uric acid (Tuomilehto et a1. 1988).
Risk Factor for Cardiovascular Disease and Diabetes Mellitus
Numerous studies indicate that some populations with NIDDM share several
common casual factors with cardiovascular disease and in particular with coronary heart
disease (perry et a1. 1995). Hyperuricemia is one ofthe common conditions of these two
disease states (Perry et a1. 1995). Several studies have found hyperuricemia to be an
independent predictor of ischemic heart disease and total mortality. Others have
concluded that the apparent connection is due to other related factors such as
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hypertension, obesity, and hyperlipidemia (Freedman et aI. 1995). Regardless of
disagreements, the relationship ofhyperuricemia with other causal factors for
cardiovascular disease and diabetes mellitus has received scant attention even though
obvious relationships exist (Zimmet 1993).
Hyperiosulinemia
Hyperinsulinemia is a state of abnonnally elevated insulin in the blood for a given
plasma glucose concentration (Zimmet 1993). Hyperinsulinemia, then, can occur in the
presence ofnormoglycemia or hyperglycemia (Zirnrnet 1993). Hyperinsulinemia is most
commonly associated with the terms "insulin resistant" or "insulin insensitive" which
indicate a resistance to insulin mediated glucose uptake (perry et aI. 1995). The resistance
to the effect of insulin is a fundamental aspect ofNIDDM and obesity (Zimrnet 1993). In
fact, insulin resistance, characterized by hyperinsulinemia, is commonly thought to be the
underlying metabolic abnonnality explaining the association between obesity.
hypertension, hyperlipideniia, and glucose intolerance, all components of the Obesity-
Insulin Resistance Syndrome (Lee et al. 1995, Vuorinen-Markkola and Yki-Jarvinen
1994).
Incidence
Hyperinsulinemia is a characteristic feature of populations with a high prevalence
ofNIDDM, such as Pima Indians, other American Indians, Micronesian Nauruans,
Mexican Americans, Australian Aborigines, Hispanics, Asian Indians, and African
Americans (Zirnrnet 1993). In the Strong Heart Study examining American Indians on
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tribal rolls from Arizona, Oklahoma, and North and South Dakota, the majority ofthose
studied were found to be insulin-resistant determined by high fasting plasma insulin levels
(Howard et al. 1995). Over 60% ofthe Arizona Indians exhibited NIDDM. Diabetes was
more prevalent in women in all three locations with 40% showing symptoms in both
Oklahoma and the Dakotas. Over one third ofthe men in Oklahoma and North and South
Dakota had NIDDM. Thirteen to 200.10 of the subjects at all three locations exhibited IGT
(Welty et aI. 1995). Obesity was very common in subjects from all three areas with the
majority ofbody fat deposited in upper-body regions as determined by waist to hip ratios.
Obesity is ofconcern in American Indians for its apparent affect on the development of
both cardiovascular disease and diabetes mellitus (Howard et al. 1995).
Modan et al. (1987), using a representative population in Israel, found IGT
patients exhibited significantly increased insulin sums (the sum of 60 and 120 minute post
glucose load insulin levels) as compared to normal glucose tolerant individuals. Newly
diagnosed Type n diabetics showed significantly lower insulin sums as compared to IGT
individuals.
Hyperinsulinemia is common among hypertensive individuals, also (Cappuccio et
al. 1993). In a study ofpregnancy-induced hypertension, insulin levels were two times
higher among hypertensive pregnant women than among the controls (Kaaja et aI. 1995).
Perry et al. (1995) state that insulin resistance antedates NIDDM. As NIDDM
progresses, many changes in glucose tolerance occur (Zimmet 1993). The presence of
hypoinsulinemia or hyperinsulinemia, thus, depends on the actual stage of the disease.
Hyperinsulinemia observed during IGT is a result ofincreased insulin secretion by the
17
pancreas (DeFronzo 1988). Once the fasting glucose level exceeds 120 mgldL, indicating
the presence of diabetes-like symptoms, the pancreas decompensates by progressively
decreasing insulin secretion even though hyperglycemia persists (DeFronzo 1988). This
inverted U-shaped curve relating insulin secretion to the fasting plasma glucose
concentration has been termed the "Starling curve of the pancreas" (DeFronzo 1988). An
individual at the transition point ofIGT to NIDDM will exhibit hyperinsulinemia whereas
a person with NIDDM studied at the stage when pancreatic decompensation has taken
place will show hypoinsulinemia (Zimmet 1993).
Pathophysiology
A number of studies have concluded that a defect in insulin sensitivity is present in
NIDDM, hypertriglyceridemia, essential hypertension, and obesity (Galvan et al' 1995). If
f,
target tissues are insensitive to the action of insulin, more insulin will be produced to
attempt to appropriately handle a glucose load. This increase in insulin then produces
hyperinsulinemia. Several of the postulated mechanisms for the development and
expression ofhyperinsulinemia are reviewed here.
The possible causes of insulin resistance include an abnonnal ~-cell secretory
product, circulating insulin antagonists, or a target-tissue defect in insulin action. The
latter condition is considered to be the most plausible cause of insulin resistance
(DeFronzo 1988).
Zirnmet (1993) reports that insulin resistance seems to be the cause ofglucose
intolerance in the majority ofadult, nonobese patients with NIDDM and in obese subjects.
A reduced number of insulin receptors could cause this insulin resistance and subsequent
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glucose intolerance and hyperinsulinemia (Zimmet 1993). Others believe both binding and
postbinding defects cause insulin resistance in NIDDM (DeFronzo 1988). Individuals
with IGT or very mild diabetes seem to experience diminished .insulin binding and then
exhibit hyperinsulinemia. Postbinding defects, on the other hand, have been observed in
fully developed NIDDM patients. These include diminished tyrosine kinase activity,
decreased glucose transport, impaired glycogen synthase activity, and reduced pyruvate
dehydrogenase stimulation (De Fronzo 1988).
Considerable debate continues over.which occurs first, hyperinsulinemia or insulin
resistance (Zimmet 1993). It has been postulated that centripetal obesity stimulates the
increase ofinsulin levels (Lee et alI995). Zimmet (1993) suggests that in obese NIDDM
subjects, hyperinsulinemia may be the primary defect and insulin resistance the result. On
the other hand, perhaps tissue insensitivity to insulin is the primary defect and
hyperinsulinemia is the resultant response in nonobese NIDDM subjects.
Either way, insulin resistance in the peripheral tissues causes a rise in plasma
glucose which prompts the pancreas to increase circulating insulin concentrations. This, in
tum, furthers the tissue insensitivity to insulin by causing a down regulation of the insulin
receptors. Plasma glucose continues to rise, causing the apex ofthe "Starling curve of the
pancreas" (DeFronzo 1988). At this point, the r3-cell decompensates, insulin secretion
decreases, and hyperglycemia intensifies (Zimmet 1993).
Hyperinsulinemia and Lipid M.etabolism
Insulin resistance enhances lipolysis (Zimmet 1993); thus, hyperinsulinemia occurs
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along with dyslipidemia. Insulin resistance also impairs the ability of insulin to normally
suppress very low density lipoprotein (VLDL) secretion (Vuorinen-Markkola and Yki-
Jarvinen 1993). Thus, excessive lipolysis which frees extra FFA that incorporate into
VLDL and increased VLDL secretion both contribute to hypertriglyceridemia (Yki-
Jarvinen and Taskinen 1988). The resultant dyslipidemia presents with decreased HDL
cholesterol and increased VLDL cholesterol, which are'both risk factors for development
ofcardiovascular disease (perry et aI. 1995).
Circulating FFA concentration is suppressed quickly by insulin in normal subjects.
However, individuals with NIDDM have a reduced capacity to suppress FFA's thereby
increasing hepatic glucose output and contributing to hyperglycemia in these subjects
(Reaven 1988). This could further exacerbate hyperinsulinemia and insulin resistance
(Reaven 1991).
Risk Factor for Cardiovascular Disease and Diabetes Mellitus
The Obesity-Insulin Resistance Syndrome is considered to be a rather strong risk
factor for cardiovascular disease (Lee et al. 1995). Central to this syndrome of connected
abnormalities are hyperinsulinemia, reduced physical activity, hypertension, reduced HDL
cholesterol, increased body mass index, and increased alcohol intake (Lee et al. 1995).
Reaven (1988) coined the term "Syndrome X" to describe a cluster of symptoms very
similar to those of the Obesity-Insulin Resistance Syndrome. Syndrome X, which
increases risk ofcoronary artery disease, may be caused by insulin resistance (Foster
1989). Many studies also report an association between atherosclerotic cardiovascular
disease and NIDDM, stating that hyperinsulinemia and insulin resistance are common
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Lfactors to both conditions (DeFronzo and Ferrannini 1991). AdditionallY,the major cause
ofmortality in NIDDM is coronary artery disease (Zimmet 1993). Heart disease is twice
as common in patients with diabetes (Wingard et aI. 1995),
Through its effects on lipid metabolism, hyperinsulinemia could initiate the
deposition ofadipose tissue in the upper-body region, another well documented risk factor
for NIDDM, hypertension, and cardiovascular disease (Kaplan 1989). Hyperinsulinemia
causes increased lipolysis which, in turn, increases hepatic triglyceride production and the
resultant hypertriglyceridemia. This dyslipidemia could accelerate the development of
atherogenesis (Zimmet 1993). Lee et aI. (1995) indicate that hyperinsulinemia stimulates
the sympathetic nervous system and suppresses adrenomedullary activity, resulting in
lower HDL cholesterol levels and higher blood pressure, both risk factors for coronary
heart disease. Additionally, high abdomen to hip measurement ratios, another risk factor
for heart disease, are positively associated with fasting and postcarbohydrate insulin levels
(Lee et al. 1995).
In the presence ofhyperinsulinemia, there seems to be a high risk of coronary heart
disease, long before NIDDM develops (Zimmet 1993, Reaven 1988). In the follow-up
study of the Paris Prospective Study, two-hour post-load plasma insulin independently
predicted deaths from coronary heart disease in subjects without NIDDM (Zimmet 1993).
Thus, subjects who are destined to develop NIDDM are at increased risk ofdeveloping
coronary heart disease many years before manifestation ofdiabet~s, apparently because of
their baseline insulin concentrations (Zimmet 1993).
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Perry et al. (1995) in the British Regional Heart Study found that the risk factors
that predict cardiovascular disease also predict NIDDM. Those cardiovascular risk
factors linked with insulin resistance, such as serum triglyceride, HDL cholesterol, and
uric acid concentrations, predicted the development ofNIDDM over a decade before
onset of the disease, even after adjustments were made for body mass index, hypertension,
and presence of coronary heart disease (perry et al. 1995)
Chromium
Schwarz and Mertz (1959) first demonstrated that chromium was required to
maintain normal glucose tolerance in rats. Chromium is now identified primarily with its
role in potentiating insulin action (Mertz 1993).
Trivalent chromium was identified as the active component ofa compound termed
glucose tolerance factor (GTF) that effectively restored glucose tolerance upon
consumption (Anderson 1987). Chromium deficiency has been identified in total
parenteral nutrition patients (Brown et aI. 1986, Freund et aI. 1979, Jeejeebhoy et al.
1977). In addition, poor chromium nutriture contributes to the progressive impairment of
glucose tolerance (Mertz 1993). The nutritional requirement in humans for chromium is
apparently increased by nutritional or physiologic stress (Nielsen 1988).
Dietary Intake
In the United States, reported dietary intake of chromium has varied widely
through the years from 200-290 !!glday in 1969 to 28 J.lglday in 1985 (Anderson and
Kozlovsky 1985). Dietary chromium intakes reported before 1980, though. should be
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questioned. Many were flawed by contamination and analytical problems (Nielsen 1994).
Increased knowledge ofcontamination issues and improved instrumentation in chromium
research is credited for the marked decrease in chromium values, rather than a dramatic
decrease in actual dietary intake (Anderson 1987).
More than 900!cJ ofpeople studied in the United States and several other countries
regularly consume diets providing less than the minimum Estimated Safe and Adequate
Daily Dietary Intake (ESADDI) ofchromium of50 J.1g1day recommended by the National
Academy of Sciences (Anderson et al. 1991, Food and Nutrition Board 1989). Numerous
studies have found no adverse consequences as the result ofthis low chromium intake
(Nielsen 1994). In 1985, Anderson and Kozlovsky measured chromium intake of 10 men
and 22 women with self-selected diets. Average chromium intake was 33 Ilglday in 2300
kilocalories for the men, indicating about 14 J.1g11000 kilocalories. The women exhibited
slightly higher intakes of25 J.1g1day in 1600 kilocalories averaging about 16 1lg/1 000
kilocalories (Anderson and KozIovsky 1985). These ranges of average chromium intake
in the United States are approximately halfof the lower limit of the ESADDI which is 50-
200 Ilglday for adults (Food and Nutrition Board 1989). Even institutionally planned
diets with well-balanced menus did not provide adequate chromium based on the ESADDI
(Anderson et aI. 1992). Perhaps, then., the current ESADDI for chromium which was
originally adopted in 1980 when measurement techniques needed improvement, might be
higher than needed by most healthy adults (Stoecker 1995). In contrast, marginal dietary
intake of chromium over many years can lead to a depletion ofchromium in the human
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body which could detrimentally affect at-risk populations such as the elderly and the
glucose intolerant (Offenbacher and Pi-Sunyer 1980).
A study examining chromium content in breast milk found that infants consuming
human milk received only an average of0.18 J.1g/L (Anderson et al. 1993). Apparently,
breast milk chromium concentrations are not significantly altered with increased maternal
dietary intake ofchromium (Casey and Hambidge 1984). Thus, when an infant consumes
an average of715 mUday of breast milk, the child would receive less than 2% of the
minimum ESADDI of 10 Ilg/day for infants less than 6 months old (Anderson et a1. 1993).
Once again, researchers wonder if ESADDI values need to be redefined to represent
actual intake (Anderson et al. 1993).
Dietary sources of chromium are scattered. Apparently, processing techniques
remove natural chromium in the case ofrefined sugar, and at other times add chromium as
in processed meats (Kumpulainen 1992). Significant amounts ofchromium may be added
to the food supply through use of stainless steel cookware in food preparation and
processing. Chromium leaches out of the stainless steel in an acid environment present in
many food products (Offenbacher and Pi-Sunyer 1983). Anderson et al. (1992) indicates
that the best sources of chromium include processed meats, whole grain products, and
spices in contrast with poor sources such as dairy products, fruits, and vegetables.
Brewer's yeast has traditionally been considered the best source of chromium, but Iraqi
barley may be an even richer source (Mahdi 1995). In Anderson and Kozlovsky's study
(1985), dietary chromium intake significantly and positively correlated with potassium, fat,
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saturated fat, sodium, oleic acid, phosphorous, vitamin B6, protein, carbohydrate and
copper intake.
Absorption
Although little is known about the specific mechanisms involved in chromium
absorption, chromium has been observed in the urine within two hours of ingestion,
indicating rather rapid absorption and excretion rates (Anderson 1987). Increased urinary
chromium losses seem to indicate an increase in chromium mobilization and utilization.
Apparently, chromium is rapidly lost in the urine rather than reabsorbed after it has
responded to a glucose load or an elevated insulin response (Anderson et aI. 1990).
Intestinal absorption of trivalent chromium and inorganic chromium compounds is
low. In contrast, hexavalent chromium absorption may be several fold higher than
trivalent chromium (Anderson 1987, Stoecker 1995). Absorption ofchromium has been
reported in ranges from <0.5% to 2-3% (Stoecker 1995). Absorption of chromium is
inversely related to dietary intake when ingested diets contain less than 40 IJ.glday,
indicating a highly efficient method ofmaintaining sufficient chromium stores (Anderson
and Kozlovsky 1985). Urinary chromium excretion can be used as a fairly accurate
estimation of the amount ofchromium absorbed since absorbed chromium is primarily
excreted in the urine (Anderson and Kozlovsky 1985). Anderson and Kozlovsky (1985)
found that when dietary chromium intake was 10 Jlglday, 2% was excreted in urine
indicating that around 2% was absorbed. When 40 Jlglday ofchromium was ingested,
0.4% to 0.5% was excreted in the urine and thus assumed to represent absorption
(Anderson and Kozlovsky 1985). Subjects with sufficient chromium stores lose more
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chromium in the urine in response to a glucose load than do subjects with depleted
chromium stores. Urinary chromium losses may depend upon th,e glucose tolerance of
subjects and whether any glucose intolerance is a chromium related deficiency (Anderson
et ai. 1991).
Chromium is best absorbed in the midsection ofthe small intestine in the rat,
followed by the ileum and duodenum. In addition, rats who have been deprived of food
absorb chromium faster than do fed rats (Chen et al. 1973).
Absorption ofchromium is also altered by mineral status. In zinc deficient rats,
whole-body and intestinal mucosa chromium absorption were increased. When oral zinc
was administered, though, the increase in intestinal mucosa chromium absorption was
decreased (Hahn and Evans 1975). These investigators also found that chromium
inhibited 6SZn absorption in zinc deficient rats and decreased the intestinal mucosa content
ofthis isotope, suggesting that chromium and zinc may share a common pathway in
metabolism (Hahn and Evans 1975). Iron and chromium may also share a common
mechanism. In one study, iron deficient animals absorbed more chromium than iron
supplemented controls. When iron was administered orally to the deficient animals,
chromium absorption was inhibited (Hopkins and Schwarz 1964).
Chromium absorption is also altered by dietary components and drugs. Chen et al.
(1973) observed that oxalate increased and phytate decreased trivalent chromium
transport in the rat intestine. Dietary carbohydrate sources affect chromium absorption
and retention. Starch appeared to increase chromium absorption in obese and lean mice as
compared to sucrose, glucose, and fiuctose as dietary carbohydrate sources (Seaborn and
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Stoecker 1989). Dietary starch also increased tissue chromium concentrations in this
study (Seaborn and Stoecker 1989). Anderson et al. (1990) supported these findings by
indicating that human diets habitually high in simple sugars lead to elevated urinary
chromium losses as compared with diets high in complex carbohydrates. Even over-the-
counter (OrC) drugs affect chromium absorption. In rats, aspirin increased SICr
absorption from 5ICrCh while Maalox decreased absorption of this isotope (Davis et al.
1995). Seaborn and Stoecker (1990) investigated the effects of antacids on tissue
accumulation and urinary excretion ofslCr. These researchers found that antacids have a
negative effect on chromium absorption from chromium chloride. In addition, Kamath
and associates (1996) determined that indomethacin, which blocks prostaglandin synthesis,
enhances SICr absorption. In contrast, 16,16-dirnethylprostaglandin E2 decreased SICr
absorption in this study (Kamath et al. 1997). Indomethacin is an OTC nonsteroidal
antiinflammatory drug commonly used for the treatment of arthritis.
Distribution
Once absorbed, trivalent chromium combines with the a-globulin portion of the
plasma and is transported or distributed to the tissues while bound to transferrin
(Anderson 1987). Chromium is widely distributed in the body with no known
accumulations or concentrations in any specific tissues or organs (Anderson 1987).
Chromium concentrations have been reported to be greater in samples of human aortas
from areas ofthe world where atherosclerosis is rare as compared to aorta samples from
areas where the disease is prevalent (Newman et al. 1978). Caution should be used,
though, in considering data obtained when chromium sampling and analysis methods were
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subject to numerous contamination problems. Various tissues seem to retain chromium
much longer than the plasma does, suggesting no equilibrium exists between tissue stores
and circulating chromium (Mertz 1993). Therefore, plasma or serum chromium levels
may not accurately indicate chromium body stores and nutritional status.
There is presently no reliable method for accurately assessing the chromium status
ofan individual (Mertz 1993). Urinary chromium reflects recent intakes. Hair
concentrations have not been unequivacaUy shown to be an acceptable method of
determining an individual's chromium status (Anderson et al. 1985). As indicated above,
serum chromium concentrations are not in equilibrium with body stores, and thus, cannot
be utilized either (Mertz 1993). The only method currently available to measure
chromium status is to analyze an individual's response to chromium supplementation,
which cannot be used as a clinical screening tool (Anderson et al. 1985).
Chromium Deficiency
Impaired glucose tolerance is one of the first physiological signs ofchromium
deficiency (Doisy et al. 1976). In the human, glucose and lipid metabolism abnormalities,
neuropathy, and encephalopathy have subsequently occurred. In animal models, impaired
growth, decreased longevity, aortic plaques, corneal lesions, and decreased fertility and
sperm count have aU been observed manifestations of chromium deficiency (Anderson
1987).
In 1977, a patient who had been receiving only total parenteral nutrition for three
years experienced weight loss, peripheral neuropathy, glucose intolerance, and an
increased caloric requirement for weight maintenance. Measured respiratory quotient
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indicated the use of fat as the major energy source even though daily infusions ofglucose
and insulin were being received (Ieejeebhoy et aI. 1977). After an infusion of250 Ilg
chromium as chromium chloride was given for two weeks, plasma glucose returned to
within the normal range after only three days indicating a possible chromium deficiency in
the patient. Increases in urinary excretion ofchromium with continued infusions
eventually leveled suggesting a resaturation ofchromium stores after 7 days of
supplementation (Jeejeebhoy et a1. 1977). Two subsequent examples ofchromium
responsive glucose intolerance have·been documented in patients also sustained with total
parenteral nutrition (Brown et aI. 1986, Freund et aI. 1979, Mertz 1993).
In the general population consuming regular diets with varied chromium content,
chromium deficiencies are not acute or simply observed (Nielsen 1988). In addition, there
is not a reliable method to diagnose chromium deficiency at this time (Mertz 1993). As a
result, some scientists consider chromium to be nutritionally insignificant (Nielsen 1988).
Other investigators, though, have shown chromium to be nutritionally significant if the
organism is under some form of stress that enhances its need for chromium (Nielsen
1988). Metabolic stress may intensitY chromium deficiency symptoms and increase
chromium's essentiality in selected subjects (Nielsen 1988). Other stresses including
trauma, infection, surgery, intense heat or cold, and even exercise alter glucose
metabolism and affect chromium metabolism (Nielsen 1988).
Chromium and Glucose Metabolism
Nearly 40 years ago, a new dietary compound termed the glucose tolerance factor
(GTF) was identified by Schwarz and Mertz (1957). This biologically active compound
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which is very richly found in Brewer's yeast (Mertz 1975), has been postulated to contain
nicotinic acid, glutathione, and chromium (Toepfer, et aI. 1977). Further research has
been unsuccessful at confinning the actual components ofGTF. Mertz, Roginski. and
Schwarz (1961) studied the effect ofGTF with trivalent chromium on glucose uptake by
peripheral tissues using rat epididymal fat in vitro. These investigators demonstrated that
very small amounts ofchromium enhanced the conversion ofglucose to fat by 70 to 95%
(Mertz et al. 1961). In later studies, GTF appeared to facilitate the binding of insulin to
receptor sites ofsensitive tissues (Mertz 1~75). In laboratory testing, GTF in Brewer's
yeast acutely improved glucose and blood lipid concentrations within minutes in
genetically diabetic mice (Tuman et aI. 1978). As a result ofthese conclusions, GTF with
trivalent chromium has been proposed to be necessary for the maintenance ofnormal
carbohydrate metabolism (Tuman et al. 1978).
Govindaraju et al. (1989) has since concluded that chromium assembles insulin and
the receptor units in cell membranes, furthering the support for the beneficiary role of
trivalent chromium in glucose metabolism. Using a GTF mixture formed in his laboratory,
a researcher in Israel observed significantly decreased blood glucose and free fatty acid
levels in streptozotocin-induced diabetic rats within two hours of injection (Mirsky 1993).
In another study, both diabetic and non-diabetic elderly patients supplemented with a
chromium rich brewer's yeast mixture exhibited significantly improved glucose tolerance
and decreased insulin output (Offenbacher and PiSunyer 1980). These results further
support the assumption that trivalent chromium within the biologically active molecule
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GTF may be essential for optimal insulin function and glucose disposal in mammals
(Offenbacher and PiSunyer 1980).
Many studies have chosen to isolate trivalent chromium outside ofany GTF
compound, and study it as a sole contributor to glucose homeostasis. Rats fed a low
chromium diet in a strictly controlled environment designed to decrease chromium
contamination showed uniform and severe impairment ofglucose tolerance in addition to
depressed growth indicating a chromium deficiency (Mertz et al. 1965). When
supplemented with 5 ppm hexa-aquo chromium trichloride, these deficiency trends seemed
to reverse. These results supported the conclusion that chromium enhances the effects of
insulin by facilitating the initial reaction of insulin with the insulin receptor sites on
membranes in the peripheral tissues (M.ertz et aI. 1965). In another study, rats fed a
moderately chromium deficient diet exhibited hyperglycemia, glycosuria, depressed
growth, and early mortality once again supporting the essentiality of chromium in animals
(Schroeder 1966).
In humans, chromium deficiency has been observed in three patients dependent on
long term total parenteral nutrition (Brown et al. 1986, Freund et al. 1979, Jeejeebhoy et
aI. 1977). All three patients experienced weight loss, glucose intolerance, and increased
exogenous insulin requirements, with one even experiencing peripheral neuropathy.
Chromium supplementation reversed these diabetic like symptoms (Brown et aI. 1986,
Freund et al. 1979, Jeejeebhoyet al. 1977). Chromium enhances the effects of insulin to
lower serum glucose (Mertz et a1. 1965). Thus, insulin must be present in order for
chromium to potentiate its action.
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Chromium seems to only restore deficient functions to normal, indicating that it
only has a physiological effect, not a pharmocological effect (Mertz et al. 1965). Thus,
the effect of supplemental chromium depends on the degree of deficiency (Mertz et at
1965). Anderson et al. (1991) found that hyperglycemic subjects who consumed diets low
in chromium «50 J.1g1day) experienced detrimental effects on their glucose tolerance and
insulin and glucagon levels. Thus, the effect of supp.lemental chromium also depends on
the degree ofglucose intolerance (Anderson et al. 1991). Mertz (1993) recently reviewed
15 controlled studies oftrivalent chromium supplementation in subjects with varied states
ofglucose tolerance. In 12 ofthe 15 selected studies, chromium supplementation
improved the efficiency of insulin.· Those studies with impaired glucose tolerant subjects
reported greater responses to chromium supplementation (Mertz ·1993). In this review,
Mertz (1993) lists two hypotheses to summarize the role ofchromium in glucose
metabolism. First, marginal chromium status contributes to the progressive impairment of
glucose tolerance with age. Secondly, marginal chromium nutriture may increase the risk
ofdiabetes and possibly coronary heart disease (Mertz 1993).
Chromium and Lipid Metabolism
Schroeder (1968) hypothesized over twenty-five years ago that chromium
deficiency was a significant risk factor for cardiovascular disease. Atherosclerosis has
been shown to be related to abnormalities in both glucose and lipid metabolism (Newman
et aI. 1978). In addition, atherosclerosis is the primary cause ofdeath in patients suffering
from diabetes mellitus (Zimmet 1993). Since normal serum lipids depend upon nonnal
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glucose tolerance and nonnal insulin sensitivity, adequate chromium nutriture may help
maintain nonnal serum lipids (Riales and Albrink 1981).
In areas of the world where atherosclerosis is mild or virtually absent, samples of
human aortas were found to contain more chromium than did samples from coronary
artery disease-prone areas (Schroeder 1968). Newman and associates (1978) also
determined that chromium might be an important factor in coronary artery disease. These
investigators measured serum cholesterol, triacylglycerols, and chromium concentrations
in subjects referred for selective coronary arteriography (Newman .et al. 1978). The
appearance ofcoronary artery disease was found to be significantly related to reduced
serum chromium concentrations and elevated serum triacylglycerol concentrations.
Lee and Reasner (1994) investigated the effects ofsupplemented chromium
picolinate on the lipid profile ofHispanics with·NIDDM. Supplemented chromium
picolinate was associated with an 17% average reduction in plasma triglyceride l.evels,
which would indicate a possible, subsequent reduction in atherosclerotic disease risk. No
differences were found in LDL-cholesterol or HDL-cholesterollevels (Lee and Reasner
1994). In this study, Lee and Reasner (1994) assumed the patients were chromium
deficient since all but two had undetectable plasma chromium levels «0.2 J.l.gIL.) using the
flameless atomic absorption spectrometry method. According to Offenbacher et al.
(1996), though, average chromium concentrations in serum or plasma are near the
detection limits ofcurrently available instruments, including the atomic absorption
spectrophotometer; thus, these parameters do not appear to be good indicators of
chromium status.
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In a study of23 middle aged men, ingestion ofa trivalent chromium solution for
twelve weeks resulted in a significant increase in HDL-cholesterol and a decrease in body
weight, serum insulin and serum glucose levels as compared to controls (Riales and
A1brink 1981). The largest improvements in HDL-cholesterol and insulin and glucose
were found in those subjects exhibiting baseline hyperinsulinemia, but normal glucose
tolerance (Riales and Albrink 1981).
Vinson and Bose (1984) separated 23 subjects into groups of normal,
hyperglycemic, insulin dependent diabetes meUitus (IDDM), and NIDDM patients. Each
subject took a high potency organic chromium yeast tablet for six months. After two
months of chromium supplementation, all groups showed improvements in percent
glycosylated hemoglobin, serum glucose, HDL-cholesterol, LDL-cholesteroL and
triglycerides. After six months of supplementation, th0ugh, only the hyperglycemic group
continued to exhibit improved blood glucose control, lowered serum lipids, and thus, a
decreased risk of coronary heart disease (Vinson and Bose 1984).
A long term total parenteral nutrition patient experiencing chromium deficiency
symptoms exhibited very high plasma free fatty acids and a low respiratory quotient,
suggesting that fat was being used as a major energy source (Jeejeebhoy et al. 1977).
After chromium infusion in the parenteral solution, plasma free fatty acids decreased to a
level only slightly higher than the nonnal postprandial range. A subsequent rise in the
respiratory quotient indicated a return of normal utilization ofglucose for energy
(Jeejeebhoy et al. 1977).
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In elderly subjects presumed to be rather chromium deficient, serum cholesterol
and total lipid levels were significantly improved in both diabetic and non-diabetic groups
receiving a chromium rich supplement ofBrewer's yeast compared to those who received
a chromium poor supplement source oftorula yeast (Offenbacher and PiSunyer 1980).
Reduced serum triglyceride levels were only observed in subjects having cholesterol levels
>300 mg/dL (Offenbacher and PiSunyer 1980).
In animal studies, Mirsky (1993) found a decrease in blood glucose and free fatty
acids in diabetic rats injected with a GTF preparation extracted from yeast extract powder,
in the absence of exogenous insulin. The decrease in free fatty acids was observed. within
thirty minutes and lasted 24 hours (Mirsky 1993). Abraham and associates (1991)
observed a marked reduction in aortic weight and cholesterol content and the percentage
of aortic intimal surface co¥ered by plaque in rabbits injected with potassium chromate
and chromium chloride while consuming a cholesterol-enriched diet. In another study
with rats, chromium picolinate, a lipophilic complex, produced a significant increase in
membrane fluidity. This chromium complex also increased insulin internalization in
cultured rat skeletal muscle cells accompanied by a marked increase in the uptake of
glucose (Evans and Bowman 1992).
Copper
Studies have reported copper to be inadequate in diets of Americans ofall ages
(pennington et al. 1986). Low dietary copper intakes are reflected in subnormal blood
copper concentrations in all animals studied (Davis and Mertz 1987). Copper status is
currently measured by serum copper, ceruloplasmin, and erythrocyte superoxide
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dismutase. All three indicators decline with frank copper deficiency but none appear to be
sensitive to marginal copper status (Tumland 1988)
In addition, many dietary components interact with copper and alter copper status.
The bioavailability ofcopper is influenced by the dietary levels ofcopper, zinc and
molybdenum, ascorbic acid, carbohydrates including fructose, glucose and starch, fiber,
phytate, some drugs, and the presence of iron deficiency (Turnland 1988).
Copper serves as an extracellular scavanger for oxygen radicals to protect cell
membranes (Linder 1991). Copper may facilitate iron transport (Linder 1991) and assist
in the oxidation of iron (Turnland 1988). Copper plays a vital role in the cross linking of
collagen, skeletalmineralization, and myelin fonnation (TurnJand 1988). Copper is
required by all cells for oxidative phosphorylation (Linder 1991). Copper also has
physiological roles in the integrity of the cardiovascular system, immune function,
regulation of glucose metabolism, and lipid and cholesterol metabolism (Davis and Mertz
1987). Copper is an essential component ofmany enzymes, including but not limited to
cytochrome oxidase, Iysyloxidase, superoxide dismutase, and ceruloplasmin (Tumland
1988).
Dietary Intake
In 1989, the National Academy of Sciences readjusted the ESADDI of copper for
adults to 1.5 to 3 mg/day from 2 to 3 mg/day to maintain copper balance with a margin of
safety (Food and Nutrition Board 1989). Based on the ESADDI values for each age
group for copper, Pennington et al. (1986) determined that usual diets of infants, children,
teenagers, adult women and men, and elderly women and men were all low in copper.
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The average intake for adult women was 0.93 mg/day and 1.24 mg/day for adult men
(pennington et al. 1986).
Balance studies have indicated an adult male requires 1.3 mg/day of copper
(Tumland 1988). Klevay and associates (1980) found the copper requirement for an l!dult
male to be 1.55 mg/day including an estimated surface loss of0.25 mg/day. Many
conventional diets did not meet this requirement when tested (Kievay et al. 1980).
Tumland (1988) has suggested the dietary recommendations be reevaluated for copper.
Reportedly, the amount ofcopper required for balance is directly related to the
amount ofdietary zinc consumed (Sandstead 1995). In one study, zinc accounted for
nearly 30% ofthe variance in the copper requirement (Sandstead 1982) while protein
accounted for 3% ofthe variance (Sandstead 1982) Abnormalities have been seen with
zinc to copper ratios greater than 16 (Sandstead 1995). Apparently, persons who
habitually consume diets high in zinc and low in protein have an increased risk of
becoming copper deficient. Requirements for copper are lowest when protein intake is
high and zinc intake is low (Sandstead 1982).
The content of copper in foods is influenced by many fact0rs. Measured values of
copper in any food item will reflect its origin and its production, handling, and preparation
conditions (Davis and Mertz 1987). In some areas of the world, copper contamination
from use of fungicides and fertilizers made with copper compounds will increase copper
concentrations in plants and animals grown there (Davis and Mertz 1987). Foods rich in
bioavailable copper include liver, oysters, peanut butter, nuts, legumes, mushrooms, and
whole grains. Meat and dairy products are low in copper (Sandstead 1995). Drinking
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water contains highly variable concentrations of copper influenced by the interaction of the
water's acidity with the piping system (Food and Nutrition Board 1989).
Absorption
It is believed that intestinal absorption of copper is regulated by the nutritional
status of the individual, the chemical form ofthe element, and the interactions with other
dietary factors that affect bioavailability (Davis and Mertz 1987). Copper seems to be
absorbed in all segments of the gastrointestinal tract with the small intestine being the
major site ofabsorption (Davis and Mertz 1987). Some minimal absorption occurs in the
stomach in man (Linder 1991).
Metallothionein is believed to be a copper binding protein (prasad 1993) that is
involved in the regulation of intestinal absorption of copper (Davis and Mertz 1987).
Cunnane et a1. (1985) observed higher absorption rates ofcopper in the presence ofa
copper deficiency as compared to adequate copper nutriture in the rat.
Low concentrations ofdietary copper are predominantly transported by a saturable
mechanism utilizing active transport. Conversely, high concentrations use an unsaturable
mechanism with simple diffusion (Davis and Mertz 1987).
There are powerful exogenous factors that also seem to regulate copper
absorption. The presence ofother minerals and dietary components can strongly affect the
biological availability of copper. In addition, the chemical form in which copper is
ingested also influences its bioavailability. Neutral or anionic copper complexes were
better utilized in one study than equivalent amounts of copper sulfate (Davis and Mertz
1987).
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Dietary intake ofseveral minerals and organic substances may affect copper
absorption. Phytate from dietary fiber may impair the bioavailability ofcopper (Sandstead
1982). Picolinic acid may facilitate copper absorption when it fonns complexes w.ith
copper (Sandstead 1982). Fructose exacerbates the severity ofcopper deficiency
symptoms (Fields et al. 1983c, Fields et aI. 1984, Henry et aI. 1991) while replacement
with cornstarch reduces or prevents copper deficiency symptoms (Fields et aL 1983c,
Fields et aI. 1984, Turriland 1988). Ascorbic acid depresses copper bioavailability (Davis
and Mertz 1987). Hunt et aI. (1970) found that adding ascorbic acid to the purified diets
ofchicks increased the severity ofcopper deficiency. Van Campen and Gross (1968)
found less severe copper deficiency symptoms in rats fed ascorbic acid, but still found
substantial evidence that ascorbic acid can depress the intestinal absorption ofcopper.
Tumland (1988) reported that dietary levels of ascorbic acid up to 600 mg did not affect
serum copper in young men. The popularity ofvitamin C supplementation, though, could
provide even higher levels ofascorbic acid which could negatively impact copper status
(Davis and Mertz 1987).
Copper bioavailability is impaired in the presence of exce~3ivezinc (Tumland
1988). It is believed that copper and zinc compete for binding sites on metallothionein in
the intestinal mucosal cells (Sandstead 1982). Copper deficiency symptoms and
abnormalities are associated with a zinc to copper ratio greater than 16. Most Americans
maintain a zinc to copper ratio from 5 to 14 (Sandstead 1995). In addition, interactions
between copper and cadmium, iron, molybdenum, and calcium have all been documented
(Davis and Mertz 1987).
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DistributiQn
Evans and LeBlanc (1976) suggested that an intestinal binding protein in rats
regulated the passage Qf absQrbed copper thrQugh the intestinal walls intQ the blQQd.
Albumin, which binds Qnly 10% of serum CQpper, is nQW believed by SQme to be the mQst
impQrtant carrier protein for newly abSQrbed copper in the bloQdstream (Cartwright and
WintrQbe 1964a, GQrdon et al. 1987). Albumin and some Qther aminQ acids may provide
copper for uptake by the liver and other tissues contributing to systemic copper transpQrt
(Gordon et aI. 1987). Contrastingly, Darwish et al. (1984) found that histidine competed
with albumin for copper binding, which resulted in copper being transported as a free ion.
Additionally, an albumin-deficient rat injected with copper intraperitoneally transported
copper to the liver at a comparable rate to a rat with nQnnal albumin levels (Suzuki et al.
1989). Lau and Sarkar (1971) believed that a ternary coordinatiQn cQmplex between
human serum albumin, copper (ll) and L-histidine is respQnsible fQr the transpQrt Qf
copper.
Regardless ofwhich transpQrt protein is used, the liver accumulates Qrally ingested
Qr intravenQusly injected copper. CQnsequently, liver parenchymnl cell plasma membranes
might contain a specific transpQrt protein for copper (II) and related trace elements
(Darwish et aI. 1984). CQpper uptake by the liver and the kidneys has been pQstulated tQ
be regulated by the synthesis Qf metallQthiQnein in the tissues (Suzuki et at. 1989). In their
study, Suzuki and assQciates (1989) Qbserved that CQpper taken up by the Uver was bQund
tQ metallQthionein suggesting that liver uptake Qf CQpper depends Qn the induction Qf
metallothionein synthesis. From the liver, CQpper enters the bile where SQme is used fQr
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production ofintemally required liver proteins and much is incorporated into
ceruloplasmin for resecretion into the blood (Linder 1991). Ceruloplasmin is an a-
globulin that binds more than 900,/0 ofcopper in blood plasma (Cartwright and Wintrobe
1964a, Suzuki et aI. 1989) and delivers it via specific receptors to other target tissues
(Linder 1991). It is currently unknown how copper reaches cells bathed by fluids not
directly derived from blood plasma like brain and placenta cells (Linder 1991). Ultimately,
copper must be distributed to all cells in order for them to carry out oxidative
phosphorylation and other essential functions (Linder 1991).
The biliary system is the major pathway for the excretion of copper, excreting 80%
(Cartwright and Wintrobe 1964a). Approximately 16% of copper is excreted directly into
the bowel and 4% is lost through the urinary system (Cartwright and Wintrobe 1964a).
Total body copper appears to vary with the species, age, and copper status ofthe
individual (Davis and Mertz 1987). Relatively constant copper tissue concentrations
indicate sufficient dietary intake and effective homeostatic control ofcopper (Food and
Nutrition Board 1989). Normal blood levels ofcopper in healthy animals range between
0.5 to 1.5 J.lg/mL with most values lying between 0.8 and 1.2 J.lglmL (Davis and Mertz
1987).
During gestation, the concentration of copper in the human fetus increases greatly
with halfof the total fetal copper accumulating in the liver. It is believed that these
hepatic reserves are designed to protect the infant from copper deficiency in early life
(Food and Nutrition Board 1989). Women who are pregnant or taking oral
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contraceptives exhibit greatly elevated serum copper levels, apparently from the effects of
estrogen (Davis and Mertz 1987).
Copper Deficiency
Copper deficiency in animals results in symptoms of hypocupremia, depletion of
tissue copper, anemia, alterations in iron metabolism, skeletal changes, hair and skin
changes, neurologic disease and cardiovascular disorders (Cartwright and Wintrobe
1964b). Other biological parameters affected by copper deprivation include glucose
tolerance, connective tissue function, cholesterol and lipid fonnation, transport or
metabolism, brain development, fertility, and immunity (Linder 199]). Klevay (1980)
observed elevated serum uric acid concentrations in response to copper deficiency in male
rats.
In 1979, Mason reported that copper deficiency symptoms in humans had only
been observed in infants. In accordance with his observations, dietary copper deficiency is
not currently known to occur in adults under nonnal conditions (Food and Nutrition
Board 1989). Hypocupremia as a result of copper depletion has been noted in patients on
total parenteral nutrition support and in Menke's steely hair disease (Food and Nutrition
Board 1989), an inherited disease ofimpaired copper utilization which afflicts newborn
infants (Mason ]979).
Hypocupremia, indicating a copper deficient state, can occur from a defect in
apoceruloplasmin synthesis, low dietary intake of copper, low dietary intake of protein,
decreased absorption of copper, and a loss ofceruloplasmin through urine or bowel
excretion (Cartwright and Wintrobe 1964b). Hypocupremia has been observed in iron
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deficiency. hypoproteinemia, kwashiorkor, tropical sprue, nontropical sprue, and nephrotic
syndrome. The presence ofhypocupremia in these abnonnalities is probably not due to
inadequate dietary copper intake (Mason 1979).
As dietary copper deprivation progresses. tissue concentrations ofcopper fall with
time and the activity of copper dependent enzymes decrease (Linder 1991). Copper
concentrations in body and tissues decline with deficiency. but they are not reliable or
valid as the sole criteria of deficiency (Davis and Mertz 1987). Circulating copper is
subject to many non-nutritional factors both honnonal and infectious, in addition to the
dietary interactions affecting copper absorption (Davis and Mertz 1987) making it a rather
variable index of copper status.
In animal studies, copper deficiency symptoms have been observed with a variety
of altered factors. Streptozotocin-induced diabetic rats showed significant increased
oxidant stress indicated by alterations ofantioxidant enzyme activities when fed diets
deficient in copper (McDermott et aI. 1994). This study suggested that the observed
increase in renal and liver copper concentrations were caused by increased intestinal
absorption in the presence ofdiabetes mellitus (McDermott et aI. 1994).
Fructose has been shown to aggravate copper deficiency manifestations in
laboratory animals (Fields et al. 1984, Fields et aI. 1984, Henry et aI. 1991) when used as
the sole carbohydrate source in the diet. Female rats, though, appear to be protected from
the lethal consequences of copper deficiency and dietary fructose (Fields et al. 1992,
Henry et aI. 1991). In a study with male rats fed a high fructose and high fat diet deficient
in copper, detrimental effects on growth, tissue trace element concentrations, energy
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metabolism, and substrate availability for nucleotide synthesis were observed (Wapnir and
Devas 1995). A synergistic effect was observed with the three dietary factors ofhigh
fructose, high fat, and deficient copper (Wapnir and Devas 1995).
Fields and associates (1992) studied whether differences in copper and iron status
between male and female rats can be detected during the development ofcopper
deficiency. Male and female rats were fed either copper deficient or adequate diets with
fructose for 31 days. Fields et al. (1992) found that copper-deficient males experienced a
reduction in body weight, increase in heart and liver sizes, and a decrease in pancreas size
compared to the females who did not experience any change in organ size. In addition,
the copper deficient males were anemic and their livers showed the presence of free
radicals, while the females exhibited none of these symptoms (Fields et al. 1992).
Using pigs which have gastrointestinal tracts much like humans, Schoenemann et
al. (1990) contrastingly found no differences in copper deficiency manifestations in either
males or females between sucrose and cornstarch diets. Anemia and cardiac enlargement
developed in rats fed copper deficient diets with sucrose or fructose, but not with starch as
the carbohydrate source (Fields et al. 1984). Others have also noted such striking
reductions or prevention ofsudden death from copper deficiency in rats fed starch as
compared to sucrose or fructose (Redman et al. 1988). Fructose apparently forms a
complex with copper that has different metabolic properties (Reiser et al. 1985).
Schoenemann et al. (1990) suggested that starch spared the dietary copper requirement of
rats by an unknown mechanism.
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In humans, fiuctose ingestion in a copper deficient diet reduced cuprozinc
superoxide dismutase activity oferythrocytes as compared to starch ingestion. Fructose
had no effect on serum ceruloplasmin activity or serum copper concentrations (Reiser et
al. 1985).
In rats fed a copper deficient diet, beer consumption increased longevity nearly six
fold, lowered plasma cholesterol, lessened cardiac enlargement, and raised liver copper
concentrations. Beer also seemed to increase absorption and biological half-life of oral
radiocopper (Klevay and Moore 1990).
Considerable evidence exists that female animals are protected from severe copper
deficiency symptoms (Fields et al. 1987, Fields et al. 1992, Lynch and Klevay 1994).
Female rats also remain immunologically normal when copper deficient as compared to
males (Bala et al. 1991). The copper deficiency effects on immune response in male rats
were more pronounced in the preweanling rat, suggesting that the developing neonatal
immune system is more susceptible to the effects of copper deficiency (Bala et at. 1991).
Contrastingly, Lynch and Klevay (1994) found that female mice experienced a more
extreme form ofcopper deficiency than did males. Their animal models exhibited
reactions resembling those of humans with acute myocardial infarction: the male animals
died suddenly while the females died with thrombosis when deficient in copper (Lynch and
Klevay 1994).
Fields and associates (1987) have reported their observations of male and female
rats fed a copper deficient diet containing fructose with equal deficiencies ofcopper. The
male rats were anemic, had hypertrophied hearts and died. In contrast, the females were
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not anemic, did not show heart hypertrophy and pathology and did survive (Fields et aJ.
1987). These researchers attributed this female protection to the presence ofendogenous
estrogens and support the possibility that testosterone in the male may playa role in the
severity ofcopper deficiency observed (Fields et al. 1987).
Copper and Glucose Metabolism
Over 60 years ago, Keil and Nelson (1934) reported abnormal glucose metabolism
in rats deficient in copper. Recently, investig~tors have shown an impairment ofglucose
metabolism in copper deficient rats and humans (Davis and Mertz 1987).
In adipocytes isolated from the epididymal fat pad ofyoung rats, copper and zinc
stimulated glucose transport and increased specific insulin binding in vitro, with copper
producing a greater effect than zinc (Fields et al. 1983a). In this study, the increased
insulin binding was attributed to an increase in the number of receptor sites (Fields et al.
1983a). In streptozotocin-induced diabetic rats, insulin and copper seemed to form a
stable complex which increased insulin binding and/or decreased insulin degradation. The
effect was more significant than any seen from insulin or copper alone (Fields et al.
1983b). In male rats fed a copper deficient diet, the insulin response was delayed 30
minutes after glucose injection as compared to copper adequate rats. Thus, it appeared
likely that copper deficiency interferes with normal glucose utilization (Hassel et al. 1983).
Glycosylated hemoglobin reflects the degree ofhyperglycemia, or the
concentration ofglucose in plasma over the last two or three months in humans. Klevay
(1982) tested the hypothesis that the concentration of glycosylated hemoglobin would
46
increase in copper deficient rats. The rats fed a copper deficient diet, exhibited an 18% to
67% increase in glycosylated hemoglobin concentrations (K1evay 1982).
Few studies have investigated copper deficiency and glucose metabolism in
humans (Smith et aI. 1991). In case study reports of two men, K1evay et aI. (1986) found
that impainnent ofglucose tolerance was the chief manifestation of deficient copper
nutriture. Upon repletion with copper sulfate, glucose tolerance returned to normal in
these men (KIevay et aI. 1986).
Smith and associates (1991) studied the effects of pregnancy and glucose loading
on plasma copper levels. As pregnancy progressed, plasma copper and ceruloplasmin
activity increased. Pregnant women at 28-34 weeks ofgestation exhibited half the glucose
disappearance rate that non-pregnant women and women at 13-17 weeks ofgestation
experienced. Insulin disappearance from the peak to 180 minutes was 71.5% for non-
pregnant women, 62.5% for early pregnant women, and 39.3% for late pregnant women.
Plasma copper responses were similar, though, for all three groups suggesting that no
association exists between plasma copper and serum glucose or plasma insulin responses
in pregnancy (Smith et al. 1991).
Some investigators have proposed specific biochemical connections for copper and
glucose metabolism. Johnson and Nordlie (1977) found that physiologic concentrations of
copper inhibited hydrolysis ofglucose-6-phosphatase in vitro. They suggested this effect
would decrease the release of glucose into the blood (Johnson and NordHe 1977). Others
have shown that copper promotes glucose incorporation into fatty acid and glycerol
moieties of adipose cell glycerides (Saggerson et aI. 1976), stimulates insulin binding
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(Fields et aI. 1983c), and increases lipogenesis (Fields et aI. 1983b), and glucose oxidation
(Fields et aI. 1983c, Smith et aI. 1991).
Copper and Lipid Metabolism
Nearly 50 anatomical, chemical, and physiological similarities have been identified
in people with ischemic heart disease and animals with copper deficiency (Klevay and
Moore 1990). Hypercholesteremia is related strongly to the development of coronary
heart disease and is now considered the major risk factor for development of coronary
heart disease (Sempos et al. 1989). Many studies have reported strong effects ofcopper
deficiency in experimental animals on the metabolism of lipids, cholesterol, and on
peroxidation (Davis and Mertz 1987). Klevay (1975) hypothesized that coronary heart
disease is characterized by an imbalance in the ratio ofdietary zinc to copper. Hermann et
aI. (1993) found that elderly subjects with low copper intakes exhibited elevated plasma
lipids and plasma triglycerides.
Davis and Mertz (1987) reported that true copper deficiency results in an elevation
of serum cholesterol. Allen and Klevay (1980) found a marked elevation in plasma
cholesterol and triglyceride concentrations in the copper deficient rat. Copper deficiency
produced a significant increase in LDL-cholesterol and a significant decrease in HDL-
cholesterol in these rats (Allen and Klevay 1980). Lefevre et a1. (1986) found that rats fed
copper deficient diets developed elevated plasma cholesterol along with an increase in
HDL-cholesterol and LDL-cholesterol. Lefevre et al. (1986) confirmed through
separation techniques that the increase in HDL-cholesterol seen in their copper deficient
rats occurred in conjuction with an increase in apolipoprotein E-rich HDL-cholesterol.
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They also found that hepatic membranes. from the copper-deficient group bound
significantly fewer lipoproteins than the control group. This decreased. binding activity
was also negatively correlated. with the proportion ofHDL-cholesterol enriched. with
apolipoprotein E (Lefevre et al. 1986).
In another study. high intakes ofzinc in relation to copper induced. copper
deficiency which in tum decreased apolipoprotein A-I and HDL cholesterol and injured
the myocardium (Sandstead 1995). Koo and associates (1990) suggested that
hypercholesteremia found in copper deficient rats may be due to possible defects in the
intravascular metabolism ofcholesterol after its release from the liver. Copper deficiency
decreases lipoprotein lipase activity which may. in turn, explain the hypertriglyceridemia
and hypercholesterolemia associated with copper depletion (Koo et a1. 1988, Lau and
Klevay 1982). Croswell and Lei (1985) postulated from the results of their study that
copper deficiency may alter the structure ofapolipoprotein E or the function of lipoprotein
receptors which would impair lipoprotein-receptor binding and result in
hypercholesterolemia.
Cunnane et al. (1985) studied the effects ofcopper intake on lipid essential fatty
acids in rats. Rats with a low intake ofcopper exhibited decreased palmitic and oleic acids
and increased stearic and docosahexaenoic acids in plasma, liver, and heart phospholipids
as compared to controls. Copper was then suggested to significantly affect tissue lipid
composition ofessential fatty acids (Cunnane et al. 1985).
In dietary studies, rats fed copper deficient diets with fructose or sucrose exhibited
many cardiac abnormalities (Redman et al. 1988). Ventricular hypertrophy. mild to severe
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myocardial inflammation, degeneration, and fibrosis were found in the hearts of these
copper deficient animals (Redman et al. 1988). Ingestion ofbeer lowered plasma
cholesterol and lessened cardiac enlargement in rats fed a diet deficient in copper. The
mechanism by which beer produced. these benefits is unknown, but perhaps attributable to
a the mixture of chemicals and compounds found in beer. The authors did not attribute
these effects to alcohol, chromium, or copper levels in beer (Klevay and Moore 1990).
Salonen et aI. (1991) found elevated ~rum copper independently predicted
ischemic heart disease in a study ofmen in eastern Finland. Copper has been shown to
promote the oxidation ofLDL-cholesterol in vitro and in vivo which increases its
atherogenicity. Consequently, raised copper levels in the blood could be a risk factor for
cardiovascular disease as well as ischemic heart disease (Salonen ~t a1. 1991).
. .
BHElcdb rat as a Diabetic Model
The BHEJcdb substrain of rats was fonned in 1975 from the parent strain of rats
named BHE for the U.S.D.A. Bureau ofHome Economics (Berdanier 1991). The
BHE/cdb rat was bred to reliably manifest age-related abnonnal glucose tolerance and
glomerulosclerosis without the complications ofobesity and hydronephrosis (Berdanier
1991). The BHE/cdb rat strain is maintained as a closed colony that reliably produces
diabetes-like symptoms in 75% ofthe population (Berdanier 1991).
The BHE/cdb rat is a desirable animal model for the study of IGT. The BHE/cdb
rat is not prone to obesity, which removes a corrunon confounding factor of animal models
with diabetes (Berdanier 1991). The BHE/cdb rat develops abnonnal glucose tolerance by
50
300 days ofage, exhibits fasting lipemia, premature renal disease, and a fatty liver
(Berdanier 1991).
Mild fasting hyperglycemia and abnonnal glucose tolerance can be enhanced in the
BHE rat by feeding a diet rich in fat and sucrose (park et aI. 1986). In a study using male
weanling BHE rats, starch feeding produced less glucose through gluconeogenesis. Those
fed sucrose, though, synthesized more glucose exacerbating hyperglycemia and abnormal
glucose tolerance (park et al. 1986). In addition, age, sucrose feeding, and coconut oil
feeding all help potentiate hyperlipemia, gluconeogenesis, and decreased efficiency of ATP
synthesis (Mathews et aI. 1995). A point mutation was found in the mitochondrial DNA
gene that encodes a portion ofF1FOATPase, an enzyme that catalyzes ATP synthesis
(Mathews et al. 1995). Mathews and associates believe this mutation is powerful enough
to decrease ATP synthesis efficiency (Mathews et al. 1995), and thus affect oxidative
phosphorylation.
51
CHAPTER III
MATERIALS AND METHODS
Researcb Design
This study was designed as a 2x2 factorial experiment consisting offour diet
treatment groups with dietary chromium and copper as variables. Animals were randomly
assigned into eacll ofthe four experimental groups.
Animals
Forty male weanling BHE/cdb rats (Univ. of Georgia, Athens, GA) were housed
according to USDA and NIH guidelines for laboratory animals. To help control mineral
contamination, the rats were housed in an isolated laboratory in plastic cages with plastic
gratings. The temperature and humidity controlled laboratory was maintained by
personnel from Laboratory Animal Resources in the College ofVeterinary Medicine at
Oklahoma State University. The rats had free access to experimental diets and deionized
water for the course of the study. Deionized water was changed three times a week to
maintain freshness. Ceramic feed cups and glass water containers were used to reduce
possible mineral contamination.
Treatments
The weanling rats immediately began their assigned experimental diet after aniving
at our laboratories. The initial experimental diets were prepared by guidelines of the
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American Institute ofNutrition (AIN-93G) diet for rats (Reeves et aI. 1993), fonnulated
for growth and adaptation (see appendix A). The four diet combinations randomly
assigned were:
1)
2)
3)
4)
Adequate chromium and adequate copper
Adequate chromium and deficient copper
Deficient chromium and adequate copper
Deficient chromium and deficient copper
(+Cr+Cu)
(+Cr-Cu)
(-Cr+Cu)
(-Cr-Cu)
The mineral mix of the AIN-93G diet was altered only according to the experimental
design groups listed above. Diets with adequate chromium contained 0.1466 g chromium
chloridelkg mineral mix. Diets with adequate copper contained 0.30 g cupric
carbonatelkg mineral mix. Diets with deficient chromium contained 0 g chromium
chIoridelkg mineral mix. Diets with deficient copper contained 0.03 g cupric carbonatelkg
mineral mix. The vitamin mix was altered to contain five times the recommended level of
Vitamin E, or 0.6 g/kg diet mix, to minimize oxidative damage (Kullen and Berdanier
1992). After weights had plateaued at thirteen weeks, the diet was changed to a high fat
diet (see appendix B) with the same factorial design of mineral depletion. This high fat
diet was then given ad libitum through the end ofthe study. Experimental diet and
deionized water were available for free access through the end of the study except as
specified by the experimental protocot
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Preparation of Diets
Semi-purified diets and mineral mixes were prepared in our laboratory after
assaying diet components for trace mineral content. The mineral mixes were prepared
from reagent grade or ultrapure chemicals using the lot number found to be lowest in
chromium. Different lots have been found to vary greatly in trace mineral concentration.
Diet and mineral mix ingredients were weighed in advance. Ingredients for the mineral
mix were mixed in a burundum-fortified porcelain jar in a roller type mill for 24 hours.
Each batch ofdiet was mixed for 40 minutes to'provide consistency in diet preparation
and composition (see Appendix C). Diet was refrigerated and protected from light to
prevent the breakdown of light sensitive vitamins.
Experimental Protocol
Throughout the study, animals were weighed weekly. During the third, tenth, and
sixteenth weeks, a sample oftwenty-four animals, six from each group, were caged in
metabolic cages for urine collection, and food was withheld for six hours to create a
fasting situation. Urine glucose test strips (Clinistix, Bayer Corporation, Diagnostics
Division, Elkhart, IN) were used to test the animals for glucose intolerance. During the
twelfth, eighteenth, and twenty-first experimental weeks, baseline blood samples were
taken from the tail, and each rat was given a 1g1kg body weight glucose load in a 50%
glucose solution for an oral glucose tolerance test. Two hours later, another blood sample
was carefully taken from a cut to the end of the tail to avoid hemolysis. Baseline and two
hour blood drops were analyzed immediately on a p-glucose analyzer (HemoCue Inc.,
Mission Viejo, CA) to investigate the state of impaired glucose tolerance (IGT) and
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possible mineral depletion in the animals. For the first glucose tolerance test, the glucose
difference was determined by the difference between the baseline glucose and the 2 hour
glucose.
After twenty-one weeks on the experimental diets, the first set ofanimals was
necropsied. Four animals, one from each experimental group, were necropsied each day
for a total often days. The animals were caged in metabolic cages and food was withheld
for 12 hours overnight. The animals had free access to deionized water. Urine samples
were collected during the 12 hour fast and frozen for chemical analysis. The animals were
anesthetized with ketamine HCl (60'mg) and xylazine (6 mg) and lean body mass was
measured using the EmScan SA-2 small animal body composition analyzer. The animals
were then exsanguinated. Blood samples were collected by cardiac puncture at necropsy
using two separate syringes for plasma and serum collection. Sodium citrate was used as
the anti-coagulating agent for plasma collection. Blood collected for plasma samples was
centrifuged and separated as soon as possible. Blood for serum samples was chilled and
allowed to clot for at least thirty minutes, then centrifuged and separated. Plasma and
serum were both stored at -20°C until assayed. Tissues were removed, weighted, and
stored at -20°C.
Weight gain was expressed as the difference between final weight and initial
weight. Fat mass was determined by obtaining the difference between lean body mass and
final weight. Tissue percent body weights were determine for liver, spleen, testes, heart,
and thymus by dividing the tissue weight by the final body weight of the animal and
multiplying by 100 to obtain a percentage.
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Biochemical Analysis
Serum and Urinary Uric Acid
Serum uric acid was determined on the COBAS FARA clinical analyzer system
with a Roche reagent (Roche Diagnostic Systems, Inc., Branchburg, NJ) using a
modification ofthe Fossati method (Fossati et.al. 1980). Fossati and associates (1980)
used peroxidase to couple the hydrogen peroxide fonned by the uricase reaction that
oxidizes uric acid to allantoin. The modification uses N-ethyl-N-(2-hydroxy-3-
sulfopropyl)-m-toluidine (TOOS), which foons a chromogen with 4-aminoantipyrine in
the presence of hydrogen peroxide and peroxidase. The absorbance of the chromogen is
measured at 550 om, which is proportional to the concentration ofuric acid. Non-
hemolyzed serum was used as the specimen. Urio acid in urine was also measured using
this procedure on the COBAS FARA chemical analyzer system. Total urine uric acid was
express as mg/12 hours and obtained by the following formula:
Total urine uric acid = (urine volume x 0.01) x urine uric acid
Glucose
Serum glucose concentration was determined on the COBAS FARA clinical
analyzer system with a Roche reagent (Roche Diagnostic Systems, Inc., Branchburg, NJ)
using the procedure described by Barthelmai and Czok (1962). This procedure is an
enzymatic approach using hexokinase coupled with glucose-6-phosphate dehydrogenase
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to catalyze two reactions which ultimately yield 6-phosphogluconate and NADH
(Barthelmai and Czok 1962). When spectrophotometricaJly measured at 340 nm, the
increase in NADH concentration is directly proportional to the glucose concentration in
the sample. Non-hemolyzed serum was used as the specimen.
Insulin
Serum insulin concentrations were measured with a double radioimmunoassay
antibody technique using a rat insulin RIA kit (Linco Research, Inc. St. Louis, MO) based
on a procedure described by Morgan and Lazarow (1963). Insulin determination is based
on the ability ofa limited quantity of antibody to bind a fixed amount of radiolabeled
antigen. The Linco RIA kit utilizes an antibody made specifically against rat insulin. The
amount of radioactivity in tubes was counted using the Packard Cobra II automatic
gamma counter (packard Instrument Co., Meriden, CT) with a data reduction system.
Non-hemolyzed serum was used as the specimen. Insulin to glucose ratio, an indicator of
insulin sensitivity, was determined by dividing insulin by glucose for each animal.
Xanthine Oxidase
Xanthine oxidase (xanthine:oxygen oxidoreductase, EC 1.1.3.22) is an iron-
molybdenum flavoprotein that is assumed to be the rate-limiting step in purine metabolism
(Fried and Fried 1974). Xanthine oxidase activity was measured using the methods of
Singh et al. (1987). This procedure involves the stoichiometric oxidation of2,2'-azino-
di(3-ethyl-benzthiozoline-6-sulphonate) (ABTS) in the presence of peroxidase and
hydrogen peroxide to form a chromogen. The oxidized ABTS, which is proportional to
the xanthine oxidase activity, was measured at 410nm on the Beckman DU-64
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spectrophotometer with non-hemolyzed serum samples. Repeating samples were
performed for each animal to provide a mean result. The serum specimen was stored at -
20°C after collection and manually assayed within 5 days (appendix D).
Serum Creatinine and Urinary Creatinine
Determination of serum creatinine was performed on the COBAS FARA clinical
analyzer system with a Roche reagent (Roche Diagnostic Systems, Inc., Branchburg, NJ).
Using a kinetic modification of the original Jaffe reaction (Larsen 1972), the sample is
added to an alkaline picrate solution, and absorbance is read at 500 om after a 10 second
time interval to minimize non-creatinine interferants. The absorbance measured is then
proportional to the creatinine concentration in the sample. Non-hemolyzed serum and
urine samples were used as the specimens in this procedure. Total urine creatinine was
expressed as mgl12 hour and determined by the following formula:
Total urine creatinine = (urine volume x 0.01) x urine creatinine
Blood Urea Nitrogen
Determination ofBlood Urea Nitrogen (BUN) was performed on the COBAS
FARA clinical analyzer system with a Roche reagent (Roche Diagnostic Systems, Inc.,
SomerviHe, NJ). This test is performed as a kinetic assay in which urea in the sample is
hydrolyzed by urease to ammonia and carbon dioxide. Glutamate dehydrogenase then
converts ammonia and a-ketoglutarate to glutamate and water. Concurrently, reduced
nicotinamide adenine dinucleotide (NADH) is oxidized to nicotinamide adenine
dinucleotide (NAD). Two moles ofNADH are oxidized for each mole ofurea present.
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The initial rate ofdecrease in absorbance at 340 om is proportional to the urea
concentration in the sample. This procedure used non-hemolyzed serum as the specimen.
Non-esterified Fatty Acids and 8-bydroxybutyrate
In uncontrolled diabetes mellitus, low insulin levels lead to increased lipolysis and
decreased re-esterification, thereby increasing serum non-esterified fatty acids (NEPA).
These NEFA are oxidized in the liver and result in increased hepatic' ketone production
and acetoacetate accumulation in the blood. There are three different types of ketone
bodies present in the blood: ,8-hydroxybutyrate, acetoacetate, and acetone. The
measurement of,8-hydroxybutyrate is one method ofdetection and estimation of ketone
bodies in serum (Tietz 1994).
The COBAS FARA clinical analyzer system was used to determine ,8-
hydroxybutyrate in non-hemolyzed serum with an" enzyme kit (Sigma Diagnostics, Catalog
No. 310-A, S1. Louis, MO). In the analysis of,8-hydroxybutyrate, ketones are oxidized by
3-hydroxybutyrate dehydrogenase in the presence ofNAD. This reaction forms
acetoacetate, NADH and It. NADH absorbs light at 340 om. Thus, the increase in
absorbance due to the reaction just described is directly proportional to the ,8-
hydroxybutyrate concentrations in the sample.
NEFA concentrations in serum were determined on the COBAS FARA clinical
analyzer system using the NEFA-C kit (WAKO Chemicals USA Inc., Richmond, VA).
Acyl CoA from the fatty acids, 4-aminoantipyrene, 3-methyl-N-ethyl-N-(~-hydroxyethyl)­
aniline and peroxidase are oxidized and react to form peroxide, which then forms a purple
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colored adduct, which can be measured colorimetrically 550 om. The amount ofNEFA in
the serum sample was detennined from the optical density measured at 550 nm.
Serum Triglyceride
Serum triglyceride concentrations were colorimetrically determined on the COBAS
FARA clinical analyzer system with an enzyme kit (Sigma Diagnostics, Catalog No. 339-
20, St. Louis, MO) using a non-hemolyzed serum specimen. Initially, lipase catalyzes the
triglycerides into glycerol and fatty acids. Glycerokinase then catalyzes the first of three
reactions which ultimately produce quinoneimine dye with the addition ofperoxidase. The
absorbance of quinoneirnine dye is then measured at 540 nm and is directly proportional to
the triglyceride concentration in the sample.
Total Cholesterol
Serum total cholesterol concentrations were determined using the COBAS FARA
clinical analyzer system with a Roche reagent (Roche Diagnostic Systems, Inc.,
Branchburg, NJ). Using a method fonnulated from a procedure described by Allain et al.
(1974), cholesterol ester hydrolase is added to the sample to release cholesterol from its
esters. This free cholesterol is then oxidized by cholesterol oxid~e, which produces
hydrogen peroxide. When hydrogen peroxide is combined with 4-aminoantipyrine and
phenol, a chrornophore is formed. The absorbance of this cbrornophore can be read at
500 om and is directly proportional to the cholesterol concentration in the sample. Non-
hemolyzed serum was used as the specimen in this procedure.
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FructQsamine
Fructosamine is a glycated prQtein assayed tQ indicate average glucose status Qver
a time frame Qf one to three weeks. The COBAS FARA clinical analyzer system was used
tQ determine levels Qf fiuctosamine in nQn-hemQlyzed serum samples using the RoTAG
FructQsamine Assay kit (Roche DiagnQstic Systems, Inc., Branchburg, NJ). This
cQIQrimetric test relies Qn the ability Qf ketQamines to reduce nitroblue tetrszQlium at
alkaline pH. After a ten minute delay tQ eliminate endQgenQus substance interference, the
fonnation rate offormazan is read at 550 run. This rate is then directly proportional tQ the
fructosamine concentration in the sample.
Serum Magnesium
Serum magnesium was determined on the COBAS FARA clinical analyzer using a
Roche reagent (Roche Diagnostic Systems, Inc., Branchburg, NJ) This reagent kit utilizes
the methQds Qf Ferguson et a!. (1964) by using chJorophosphonazo III as a sensitive dye
to determine magnesium spectrophotometrically. The Roche reagent then adds EDTA to
prevent calcium interference. ChlorophQsphQnazo III binds to magnesium, causing an
absQrbance decrease at 550 nm and an absQrbance increase at 675 nm. The delta
absQrbances at both wavelengths are proportional tQ the magnesium concentration in the
serum sample.
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Statistical Analysis
Data obtained from this study were analyzed as a 2x2 factorial experiment using
the Statistical Analysis System (SAS Institute Inc., Cary, NC, 1989) version 6.08. The
general linear models procedure was used for analysis ofvariance and least squares means
determination. Pearson correlation coefficients were also generated by using SAS. All
data were expressed as means ± SEM. Results were considered significant at p:5:0.05 .
..
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CHAPTER IV
RESULTS AND DISCUSSION
Three oral glucose tolerance tests were perfonned during the study. Forty rats
were included in the first and third tests while only 26 were included in the second glucose
tolerance test. A significant interaction existed between the dietary factors ofchromium
and copper in the baseline glucose results ofthe first test (Table 1). Copper had a
significant effect upon glucose within the diet groups inadequate in chromium (Table I).
Glucose was lowest in the -Cr-Cu group and highest in the -Cr+Cu group. Overall, the
first glucose toleranc.e test exhibited the highest blood glucose on average. possibly
indicating a more impaired state ofglucose tolerance early in the study than later (Table
1). The BHElcdb rat is considered to be genetically predisposed to non-insulin dependent
diabetes mellitus (NIDDM), and was expected to have the characteristics ofage-related
hyperglycemia (Berdanier 1991). Chromium deficiency has produced elevated blood
glucose in past studies (Li and Stoecker 1986). In humans. Anderson et aI. (1991) states
that consuming diets low in chromium leads to detrimental effects on glucose tolerance in
hyperglycemic subjects. In the present study, depleted copper decreased glucose within
the depleted chromium groups in the first glucose tolerance test. This contradicts the
findings by Hassel et al. (1983) of significantly increased plasma glucose levels in copper-
deficient rats.
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Urine creatinine was measured on the urine collected during the fasting period of
the three glucose tolerance tests and converted to total urine creatinine for each test.
During the second glucose tolerance test, copper had a significant effect upon total urine
creatinine (Table 2). The experimental groups with deficient copper exhibited significantly
higher total urine creatinine than those groups with adequate copper (Table 2). This
finding possibly indicates less efficient kidney function in the copper deficient groups, as
urine creatinine can be used to assess the kidney's ability to clear waste products from the
body (Johnson J989). Increased total urine creatinine can also indicate the increased
breakdown ofmuscle tissue (Johnson 1989). The copper deficient groups with increased
total urine creatinine could actually be experiencing tissue breakdown rather than renal
insufficiency. Total urinary creatinine from glucose tolerance test 1 positively correlated
with body weight from the twelfth week during which the test was perfonned (r=0.37,
p<O.02, Table 3). Creatinine excretion can indicate the breakdown of lean muscle tissue
as muscle creatine is converted to creatinine daily (Johnson 1989). Thus, urinary
creatinine is an indicator of muscle mass. Mineral depletion could contribute to this lean
muscle mass loss (Croswell and Lei 1985, Hassel et al. 1983). Lean body mass was only
measured at necropsy. More frequent body composition tests could have shown a
relationship between urine creatinine and lean body mass during the growth period of
these animals. These correlations could then help disclose the possibility of muscle mass
wasting due to mineral depletion in these animals.
The fact that 2 hour glucose from tests 1, 2, and 3, and glucose difference were
not significantly different among the treatment groups could indicate that these animals
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never physiologically reached a state of impaired glucose tolerance (IGT) and were not
sufficiently mineral depleted. Perhaps an earlier introduction ofthe high fat diet could
have helped induce IGT in these animals. More frequent glucose tolerance tests could
have more accurately depicted the pattern ofglucose tolerance in these animals. Total
urine creatinine from glucose tolerance tests 1 and 3 also was not significantly different I.
among the treatment groups, again indicating the possibility that these animals were not
sufficiently mineral depleted to cause an early IGT state and subsequent kidney
insufficiency found in the pathophysiology ofdiabetes.
Upon necropsy, one animal showed signs of severe illness and was deleted from
the database. Thus, necropsy parameters were available from only 39 rats. In addition,
fructosamine, glucose, blood urea'nitrogen (BUN), and non-esterified fatty acids (NEFA)
were deleted for nine animals due to hemolysis of the sample. Xanthine oxidase was also
deleted for four animals due to erratic results.
Initial and final body weights were obtained from all forty rats and analyzed for the
39 remaining in the database. From these weight measurements, weight gain was
determined. There were no significant differences in initial body weight among any of the
groups (Table 4). This data was collected before any dietary treatment was begun~ thus,
these results were desired to avoid experimental error.
Lean body mass was measured on the 26 animals which could physically fit in the
measurement device. After the sick animal was deleted, 25 animals remained from which
lean body mass was detennined. Lean body mass and lean body mass as percent body
weight and fat mass and fat mass as percent body weight were not significantly different
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among the treatment groups (Table 5). Mooney and Cromwell (1995) examined the
effects ofdietary chromium picolinate supplementation on body composition of pigs.
They found that chromium picolinate significantly increased the percentage ofmuscle mass
and tended to decrease percentage offat mass (Mooney and Cromwell 1995). In humans,
though, Hallmark et aI. (1996) found no significant difference in. body weight, percent
body fat, lean body mass, and skinfold thicknesses with chromium supplementation and
resistance training. In addition, Lukaski and associates (1996) found increases in strength,
mesomorphy, fat-free mass, and muscle mass with resistance training in men independent
of the chromium supplementation.
Fat mass positively correlated with insulin (r=O.54, p=O.0052, Table 3) as did final
body weight (r=O.54, p=O.0004, Table 3). Kaplan (1989) explains that obesity, or
increased fat mass, is associated with peripheral insulin resistance. Hyperinsulinemia then
develops in an attempt to maintain euglycemia. Body weight increases with increased fat
mass, and would logically also correlate with insulin iffat mass was a significant portion of
whole body weight.
Tissue weights were expressed as percent body weight for 39 animals. On this
basis, chromium had a significant effect on liver, kidney, and spleen (Table 6). Animals
with deficient chromium diets exhibited significantly higher percent body weights of these
tissues than animals with adequate chromium diets (Table 6). Li and Stoecker (1986) also
found signficantly heavier livers in chromium deficient, genetically obese mice. In
addition, total hepatic lipid ofthe obese mice was significantly greater in the chromium
deficient groups, indicating abnorrnallipid accumulation and fatty livers in animals with
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Lchromium depletion (Li and Stoecker 1986). Upon necropsy, the animals' livers in the
present study appeared enlarged and possibly fatty in composition which could be a result
of mineral depletion or their genetic predisposition to diabetes. Seaborn and associates,
(1994), though, reported increased liver and kidney weights in chromium supplemented
guinea pigs, contradicting the results of the present study. These researchers suggested
that the increased liver and kidney tissues in chromium supplemented animals were due to
the possible involvement ofchromium in protein synthesis (Seaborn et aI. 1994). The
increased weight ofthese tissues was lean mass rather than fatty in composition (Seaborn
et aI. 1994). In addition, these guinea, pigs were chronically depleted of ascorbic acid
(Seaborn et aI. 1994), which could help explain the differences seen in our results and
theirs.
Final body weight ,and weight gain were not significantly different among the
treatment groups in this study (Table 4). In a few past studies, chromium has had a
significant effect on weight gain. Seaborn et a1. (1994) emphasized the essentiality of
chromium for animal growth. In their study, chromium deficient guinea pigs exhibited
significantly decreased body weight when compared to chromium adequate animals.
Copper deficiency has produced significantly decreased weight gain and mean body weight
in past studies (Croswell and Lei 1985, Hassel et al. 1983). Fields et al. (l983c), though,
found no significant effect of copper deficiency on growth rate. Perhaps with different
sampling times throughout the growth period of the animals, the mineral effects of
chromium and copper would have significantly affected weight gain. Fat mass and lean
body mass were also not significantly different among treatment groups (Table 5). As
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mentioned above, a different sampling design with more frequent body composition tests
during the growth period ofthe animals might find a signficant effect ofchromium and
copper. Testes, heart, and thymus as percent body weight were not significantly different
among the treatment groups (Table 6). ]n several animals, the thymus was possibly
atrophied from advanced age and maturity and sometimes hidden beneath layers offatty
tissue, making identification and complete removal nearly impossible. Thus, this tissue
was not available from enough animals in a complete and accurate form to lend itself to
~~&ance. ~
Serum insulin was not significantly different among the experimental groups, but
adequate chromium tended to increase insulin and depleted chromium tended to decrease
insulin (Table 7). This finding contradicts what has been seen in the literature (Li and
Stoecker 1986) with decreased serum insulin in the presence of adequate chromium. A
decrease in insulin with chromium depletion could indicate an effect of mineral depletion
upon insulin release in the BHE/cdb rat. In chromium deficient animals, insulin sensitivity
is decreased (Mertz et al. 1965), which can cause hyperinsulinemia as the pancreas
compensates for hyperglycemia (DeFronzo 1988). Deficient copper has been shown to
increase serum insulin (Fields et aI. 1983b) which also was not seen in this study (Table 7).
Insulin positively correlated with serum uric acid (r=O.55, p=O.0003, Table 8), which
supports the hypothesis that insulin inhibits uric acid secretion or enhances uric acid
reabsorption at the renal tubular level (Galvan et al. 1995). This positive correlation was
observed in the Normative Aging Study by Lee et al. (1995).
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Insulin positively correlated with total cholesterol (r=0.38, p<0.02, Table 8) which
was noted by Li and Stoecker (1986). This correlation is very logical in the relationship
between hyperinsulinemia and cardiovascular disease explained by many articles (Reaven
1988, Reaven 1991, Zimmet 1993). Hyperinsulinemia results in a dyslipidemia of
decreased high density lipoprotein (HDL) cholesterol and increased very low density
lipoprotein (VLDL) synthesis, which ultimately affects total cholesterol (Reaven 1991,
Zimmet 1993). Insulin also positively correlated with fat mass (r=0.54, p=O.0052, Table
3) and final body weight (r=0.54, p=O.0004, Table 3). Li and Stoec~er (1986) also found
a positive, though not significant, correlation between insulin and final body weight in
obese mice. In 1989, Kaplan explained that obesity, or increased fat mass, is associated
with peripheral insulin resistance, which in turn, increases insulin secretion to maintain
euglycemia.
Although glucose was not significantly different among the diet groups, glucose
did positively correlate with both triglyceride (r=O.40, p<0.03. Table 8) and non-esterified
fatty acids (NEFA) (r=O.47, p=O.009, Table 8). As hyperglycemia initiates
hyperinsulinemia in the insulin resistant individual, lipolysis is enhanced resulting in a rise
in NEFA (Reaven 1988, Zimmet 1993), which may be the basis for this correlation.
Hyperinsulinemia also results in a dyslipidemia described above that results in elevated
serum triglyceride concentration (Reaven 1991, Zimmet 1993).
Fructosamine indicates average glucose status over the past one to three weeks.
Therefore, this glycated protein assay assists in obtaining a more accurate estimate of the
necropsy glucose since glucose may be falsely elevated by anesthesia. Fructosamine was
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not significantly different among the experimental groups in this study (Table 7).
Fructosamine did tend to show an interaction effect, though, between chro-mium and
copper (Table 7). Within deficient chromium groups, animals with deficient copper
tended to show increased fiuctosamine as animals with adequate copper tended to exhibit
decreased fiuctosamine (Table 7). Klevay (1982) saw an increase in glycosylated
hemoglobin in copper deficient humans, supporting the results shown here. Fructosamine
also positively correlated with NEFA (r=0.44, p<0.02, Table 8). This correlation, again, is
explained by the concurrent presence of hyperglycemia and hyperinsulinemia resulting in
increased lipolysis and increased NEFA (Reaven 1988).
Serum triglyceride was not significantly affected by dietary chromium or copper,
but chromium tended to have an effect upon this parameter (Table 9). The groups with
adequate chromium tended to exhibit the highest triglyceride concentrations in comparison
to the groups with deficient chromium (Table 9). Vinson and Bose (1984) and Lee and
Reasner (1984) both reported decreased triglyceride levels with supplemental chromium in
humans with elevated triglyceride concentrations. The present study did not provide
chromium in chromium picolinate and high chromium yeast mixtures as these studies did,
which could help explain the difference in results. Triglyceride positively correlated with
both glucose (r=0.40, p<0.03, Table 8) and NEFA (r=0.66, p=0.009, Table 8). These
corrdations are again well supported and explained by Reaven (1988) and Zimmet (1993).
Hyperglycemia exacerbates hyperinsulinemia which, in tum, results in dyslipidemia and
increased lipolysis. These changes then elevate serum triglyceride and NEFA, respectively
(Reaven 1988, Zimmet 1993).
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Serum totaI cholesterol was significantly affected by dietary copper (Table 9). The
groups fed copper depletion diets exhibited decreased total cholesterol, while those with
adequate copper diets exhibited increased total cholesterol (Table 9). Allen and Klevay
(1980) and Koo et al. (1988) found significantly elevated serum total cholesterol in copper
deficient rats, contrasting with our results. Salonen et aI. (1991) reported that elevated
serum copper concentrations in 1,666 men in the Kuopio Ischaemic Heart Disease Risk.
Factor Study in Eastern FinJand independently predicted ischemic heart disease risk.
Salonen et al. (1991) reported that serum copper concentration rose with increasing age
and positively, though not signficantly, correlated with serum LDL cholesterol
concentration. Salonen and associates (1991) report a high copper content in drinking
water that is acidic, running through copper pipes. Thus, this population's diet and
environment most likely is copper· supplemented, rather than copper adequate as our
animals were. Cholesterol positively correlated with insulin (r=O.38, p<0.02, Table 8),
which, again has been intricately explained by many articles addressing hyperinsulinemia
and dyslipidemia (Reaven 1988, Reaven 1991, Zimmet 1993). Briefly, hyperinsulinemia
results in decreased lIDL cholesterol and increased VLDL synthesis, which ultimately
affects total cholesterol (Reaven 1991, Zimmet 1993).
NEFA are elevated in the serum of uncontrolled diabetics with low insulin levels
and increased lipolysis (Tietz 1994). Chromium had a significant effect upon NEFA in this
study (Table 9). Those animals with deficient chromium exhibited significantly lower
NEFA than those animals with adequate chromium diets (Table 9). Mirsky (1993) found
decreased free fatty acids in diabetic rats injected with a glucose tolerance factor (GTF)
71
...
preparation extracted from yeast extract powder in the absence ofexogenous insulin. Our
findings disagree with the results ofthe study by Mirsky (1993). The BHElcdb rat should
have a significant amount ofinsulin circulating at this early stage in their disease state
(Berdanier 1991). This hypothesis would make the BHElcdb rat significantly different
than the streptozotocin-induced diabetic rats Mirsky (1993) studied with no insulin
production from their damaged beta cells. This strong difference in serum insulin in the
rats could help explain the contradictory results we obtained. NEFA did positively
correlate with many parameters in this study, though, including glucose (r=O.47, p=O.009,
Table 8), fiuctosamine (r=O.44, p<O.02, Table 8), and triglyceride (r=O.66, p=O.OOOI,
Table 8). These results are well documented and explained by many research studies as
being intricately related abllonnalities within the "Syndrome X" described by (Reaven
1988). In a state ofhyperglycemia, hyperinsulinemia occurs to compensate for the
elevated glucose. Hyperinsulinernia then enhances lipolysis which, in turn, raises NEFA.
Hyperinsulinernia also results in dyslipidemia by decreasing HOL cholesterol and
increasing VLDL synthesis which then elevate serum triglyceride (DeFronzo and
Ferrannini 1991, Reaven 1988, Reaven 1991).
Serum magnesium was not significantly different among the treatment groups
(Table 9), but serum magnesium did positively correlate with serum uric acid (r=O.71,
p=O.OOOI, Table 8). An inverse relationship between magnesium nutriture and the
incidence of cardiovascular disease has been postulated (Arsenian 1993, Shils 1996). This
fact alone, could support the strong correlation seen between serum magnesium and serum
uric acid. The relationship may begin, though in the renal tubules. One-third of:filtered
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magnesium is absorbed in the proximal convoluted tubule, then 50-60% of the remaining
filtered magnesium is reabsorbed between the descending limb and the early distal tubule
of the kidney (Shils 1996). Ninety-eight to 100% offiltered plasma uric acid is reabsorbed
in the proximal convoluted tubule (Tietz 1994). Thus, serum magnesium and uric acid are
absorbed and reabsorbed, respectively, at the same time within the renal tubules, perhaps
explaining the positive correlation seen in this study.
Glucose, insulin, insulin to glucose ratio, fructosamine, triglyceride, and P-
hydroxybutyrate (BOHB) were not statistically different among the treatment groups.
These parameters were all expected to be significantly affected by mineral depletion of
chromium and copper. Perhaps the- sample size was t00 small to be significantly affected
after several animals' data sets were deleted for these parameters because of hemolysis. In
addition, the mineral depletion might not have been severe enough to significantly affect
these parameters. The BHE/cdb rat may also not have been in a state ofphysiologicat
IGT, causing these serum parameters not to show significant difference with the mineral
combinations used in this study. As Anderson et al. (1991) indicated, the effect of
chromium depends on the degree ofglucose intolerance.
BUN indicates the presence ofazotemia and is an indicator of renal excretory
function. Chromium had a significant effect upon BUN (Table 10). Animals with
chromium depleted diets exhibited significantly lower BUN than those with adequate
chromium diets (Table 10). The +Cr+Cu group exhibited the most elevated BUN,
indicating the possible presence ofrenal insufficiency in this group. Copper, though not
statisticaUy significant, tended to have an effect upon BUN. Those animals with deficient
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copper tended to have lower BUN than those groups with adequate copper (Table 10).
Renal insufficiency is common with nephropathy complications ofNIDDM. These
complications typically do not occur until more advanced stages of the disease state,
though. .As the glucose tolerance tests indicated, these BHElcdb rats might not have even
been glucose intolerant, much less uncontrollably diabetic at the time of necropsy.
Serum and total urinary uric acid were also examined at necropsy and found not to
be significantly different among the experimental groups (Table 10). Stoecker and
associates (1996) observed significantly elevated serum uric acid concentrations when
both dietary chromium and supplemented aspirin were low. This study instigated the
present study's investigation into the effects of chromium on serum uric acid
concentrations. Stoecker and associates (1996) used an additional factor of iron in their
study which had a quadratic effect on serum insulin, which is known to significantly affect
uric acid metabolism (Galvan et al. 1995). The fact that the present study did not include
iron and aspirin as stressors may help explain the lack of significance in the uric acid
parameters within the dietary factors of chromium and copper. In addition, Stoecker et al.
(1996) used a genetically obese mouse model which could have different metabolic
patterns than the non-obese BHE/cdb rat model. Serum uric acid did exhibit a positive
correlation with insulin (r=0.55, p=0.0003, Table 7) which lends support to the hypothesis
that insulin inhibits uric acid secretion or enhances uric acid reabsorption at the renal
tubular level (Cappuccio et a1. 1993, Galvan et a1. 1995).
Serum and total urine creatinine, serum and total urine uric acid, and xanthine
oxidase were not significantly different within the treatments of dietary chromium and
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copper d.epletion or adequacy. Many of these parameters were expected to be
significantly affected by mineral depletion of chromium and copper. Our BHElcdb rats
were not hyperinsulinemic or hyperuricemic, and, quite possibly, not physiologically
glucose intolerant either. Considering that depleted copper significantly increased total
creatinine during the second glucose tolerance test (Table 2) and that total urine creatinine
was positively correlated with weights during the first glucose tolerance test (r=O.37,
p<O.02, Table 3) it is quite possible that mineral depletion most significantly affects the
growth period in these animals.
Due to laboratory renovations, analysis of the diets through atomic absorption
spectrophotometry is not possible for this report. This spectrophotometer is also needed
to accurately determine the state ofmineral depletion in the tissues of these animals.
Thus, the lack of significance in many parameters within this specific proposal could be
elucidated by the complete analysis ofall data collected on the BHE/cdb rats depleted in
chromium and copper for twenty-one weeks.
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TABLE I
Glucose Tolerance Test Resullst
Test 1 Test 1 Test 1 Test 2 Test 3
Treatment N Glucose 0 hr. Glucose 2 hr. Glucose Difference' Glucose 2 hr. Glucose 2 hr.
(mgldL) (mgldL) (mg/dL) (mg/elL) (mg/dL)
-Cr-Cu 10 72±2 128±13 56±12 121±91 115±4
-Cr+Cu 10 82±3 133±12 51±14 113±61 120±7
+Cr-Cu 10 78±2 137±13 59±12 132±51 119±3 \0
t-
+Cr+Cu 10 77±2 136±9 59±1O 122±61 127±6
Facton P Values
Cr 0.89 0.61 0.63 0.17 0.28
Cu 0.11 0.90 0.82 0.22 0.25
Cr*Cu <0.04 0.81 0.82 0.88 0.82
t Values are means ± SEM. Oral glucose tolerance tests were done in experimental weeks 12, 18, and 21.
• Values are the difference between 2 hour and 0 hour glucose for test 1.
IN=6
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TABLE II
Total Urine Creatininejrom Glucose Tolerance restst
Test 1 Test 2 Test 3
Treatment N T. U. Creatinine T. U. Creatinine T. U. Creatinine
(mgl12 hr) (mgl12 hr) (mgl12 hr)
-Cr-Cu 10 5.21±O.59 7.11±O.421 6.8010.58
-Cr+Cu 10 4.55±O.53 4.91±O.63 1 6.36±O.50
+Cr-Cu 10 5.62±O.35 6.03±O.741 6.6S±0.34 r---r---
+Cr+Cu 10 5.35±O.40 5.29±O.361 6.42±O.51
Factors P Values
Cr 0.21 0.54 0.92
Cu 0.34 <0.02 0.50
Cr·Cu 0.69 0.20 0.83
t Values are means ± SEM. Oral glucose tolerance tests were done in experimental weeks 12, 18, and 21.
1 N=6
TABLE ill
Correlation Coefficients (r) Between Blood, Urine, and Body Composition Parameters at Necropsy and Glucose Tolerance Tests
_-,"",- I
INSULIN FINAL WT. FAT LBM T. CREAT 1 T. CREAT 3 WT.12 WT.21
Insulin 1.0000 I 0.5384 I 0.5410 I 0.0892 -0.0683 -0.0501 0.4869 0.4363(p=) 0.0004 0.0052 NS NS NS 0.0017 0.0141
Final Weight 1.0000 0.8494 0.7675 0.2493 0.1933 0.8845 0.9603
(p=) 0.0001 0.0001 NS NS 0.0001 0.0001
Fat Mass 1.0000 0.3136 0.2485 -0.0120 0.7649 0.7479
(p=) NS NS NS 0.0001 0.0001 00['-.
Lean Body Mass 1.0000 0.6921 0.5081 0.6398 0.7642
(p=) 0.0001 0.0095 0.0006 0.0001
Total U. Creatinine 1 1.0000 0.5161 0.3728 I 0.3988(p=) 0.0008 0.0194 0.0263
Total U. Creatinine 3 1.0000 -0.1531 0.1469
(p=) NS 0.3721
Weight, 12th Week 1.0000 0.9308
(p=) 0.0001
Weiebt, 21st Week 1.0000
(p=)
NS = No significance.
L-.-----
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TABLEN
Body Weights and Weight Gain at Necropsyt
Treatment N Body Weight (g) Weight Gain (g)
Initial l Finaf 113
- . -- ~ -------
-Cr-Cu 10 , 59B 523±13 464±12
-Cr+Cu 10 52±3 540±23 487±21
+Cr-Cu 10 55±4 552±19 497±17 0'1
r--.
+Cr+Cu 9 55±3 558±18 503±17
Factors P Values
Cr 0.77 0.22 0.16
Cu 0.27 0.54 0.38
Cr*Cu 0.31 0.77 0.61
t Values are means ± SEM.
I Data were obtained on the day the rats were received.
2 Data were obtained on the day of autopsy.
3 Values are the differences between initial and final weights.
~~
TABLE V
Lean Body Mass (LBM) and Fat Mass at Necropsy and as Percent ofFinal Weightt
Treatment N Lean Body Mass LBM Fat Mass Fat Mass
(g) as % ofFinal Weight (g) as % of Final Weight
-Cr-Cu 6 310±8 63±1 185±8 37±1
-Cr+Cu 7 . 330±13 65±1 174±9 35±1
+Cr-Cu ," 6 338±11 64±2 198±22 36±2 0
00
+Cr+Cu 6 341±11 64±2 194±15 36±2
Factors P Values
Cr 0.09 0.85 0.26 0.85
Cu 0.30 0.36 0.61 0.36
Cr·Cu 0.46 0.44 0.80 0.44
t Values are means ± SEM.
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TABLE VI
._-- -~ ---- _.- _. - - _. - -- _. --
Liver, Kidney, Spleen, Testes, Heart, and Thymus as Percent Body Weight at Necropsyt
Treatment N Liver Kidney Spleen
% Body Weight
Testes Heart Thymus
-Cr-Cu 10 2.70±0.07 0.6510.01 0.2310.01 0.6510.02 0.24110.005 0.04210.005
-Cr+Cu 10 2.5810.05 0.6410.04 0.2110.01 0.6210.02 0.24110.007 0.051±0.0071
+Cr-Cu 10 2.4910.07 0.5710.02 0.20±0.01 0.6210.02 0.23510.006 0.049±0.00i ......
00
+Cr+Cu 9 2.5110.04 0.6110.01 0.2010.01 0.6110.02 0.23010.006 0.04510.0072
P Values
Cr <0.03 <0.04 <0.03 0.33 0.17 0.93
Cu 0.43 0.49 0.38 0.44 0.70 0.65
Cr*Cu 0.24 0.34 0.33 0.71 0.75 0.35
t Values are means ± SEM.
IN=9
2N=7
t-----
TABLE VII
Glucose, Insulin, Insulin to Glucose Ratio, and Fructosamine at Necropsyt
-.t:- .... _.__~_ _ __ __
Treatment N Glucose Insulin Insulin : Gluc Fructosamine
(mgldL) (ng/mL) Ratio (~moVL)
x 10.3
-Cr-Cu 10 296±14 0.62±O.04 2.119±O.145 12S±4
-Cr+Cu 10 302±15 0.69±O.OS 2.3S3±O.297 117±5
+Cr-Cu 10 299±142 0.77±O.08 2.747±O.2262 124±42 N
00
+Cr+Cu 9 32S±15 1 0.SO±O.09 2.395±O.30S1 131±41
Facton P Values
Cr 0.32 0.07 0.21 0.28
Cu 0.24 0.47 0.86 0.69
Cr*Cu 0.41 0.81 0.23 0.06
t Values are means ± SEM.
IN=S
2N=9
L-.-----
I
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TABLE VIII
Correlation Coefficients (r) Between Blood Parameters at Necropsy
GLUe
Glucose
FRUC TRIG
Fructosamine Triglyceride
COOL INSULIN S.URIC NEFA S. Mg
Cholesterol (Serum Uric Acid) (Non~terified (Serum
Fattv Acids) MaQllesium)
GLUC
(p=)
FRUC
(p=)
TRIG
(p=)
eOOL
(p=)
1.0000 0.3596
0.0510
1.0000
I 0.4029 I
0.0273
0.2895
NS
1.0000
0.3189
NS
0.1951
NS
0.2972
NS
1.0000
-0.2174 -0.0488 I 0.4689 I 0.1603NS NS 0.0090 NS
-0.0436 -0.0741 I 0.4429 I -0.0250NS NS 0.0143 NS
-0.0514 -0.0203 I 0.6565 I 0.1852NS NS 0.0001 NS
I 0.3803 I 0.1318 0.3127 0.16040.0169 NS 0.0526 NS
f""l
00
~.;.-
INSULIN
(p=)
S. URIC
(p=)
NEFA
(p=)
Mg
(P=)
NS =No significance.
1.0000 I 0.5453 I
0.0003
1.0000
0.0789
NS
-0.1531
NS
1.0000
0.2522
NS
I 0.7108 I
0.0001
0.0583
NS
1.0000
TABLE IX
Triglyceride. Cholesterol, p-hydroxybutyrate (BOHB), Non-esterified Fatty Acids (NEFA), and Serum Magnesium at Necropsyt
Treatment N Triglyceride Cholesterol BOBB NEFA S. Magnesium
(J.l.Inol!L) (mg/dL) (mgldL) (mEqlL) (meq/L)
-Cr-Cu 10 115±11 104±7 7.614±O.636 0.743±O.043 2.15±O.11 1
-Cr+Cu 10 126±11 113±6 8.884±O.722 0.738±O.040 2. 15±O.062
+Cr-Cu 10 144±20 101±4 9.389±1.249 0.909±O.0663 2.21±O.OSl ~
00
+Cr+Cu 9 153±22 119±6 8.544±O.671 0.956±O.0802 2.16±O.103
Fadon P Values
Cr 0.10 0.77 0.41 <0.002 0.67
Cu 0.56 <0.03 0.81 0.71 0.74
Cr*Cu 0.96 0.40 0.23 0.65 0.74
t Values are means ± SEM.
I N=8
2N=9
3N=5
TABLE X
Serum and Total Urine Creatinine, Blood Urea Nitrogen (BUN).
Serum and Total Urine Uric Acidand Serum Xanthine Oxidase at Necropsyt
~~
Treatment N S. Creatinine T. U. Creatinine BUN S. Uric Acid T. U. Uric Acid Xanthine OJ:.
(mgldL) (mg/12 hr) (mgldL) (mg/dL) (mgl12 hr) (UIL)
-Cr-Cu 10 0.64±O.02 6.26±O.49 8.4±O.7 1.6±O.3 0.91±O.16 8.70±2.0S 1
-Cr+Cu 10 0.6S±O.02 6.10±0.21 9.9±0.5 1.8±O.1 1.06±O.09 5.04±1.412
V'I
+Cr-Cu 10.2±O.4 I 5.51±1.652
00
10 0.6S±O.02 6.32±O.65 1.8±O.3 0.88±O.09
+Cr+Cu 9 0.66±O.02 6.24±O.63 11.1±O.42 1.8±O.3 0.99±O.24 7.44±3.7S3
Facton P Values
Cr 0.79 0.84 <0.006 , 0.83 0.75 0.86
Cu 0.93 0.82 0.10 0.77 0.40 0.71
Cr*Cu 0.70 0.94 0.74 0.67 0.92 0.23
t Values are means ± SEM.
IN=9
2 N=8
3 N=7
CHAPTER V
SUMMARY, HYPOTHESIS TESTING AND RECOMMENDATIONS
Summary
The purpose of this study was to examine the effects ofdepletion of dietary
chromium or copper on selected parameters related to cardiovascular disease risk in the
BHE/cdb rat.
The BHE/cdb rat is genetically predisposed to non-insulin dependent diabetes
mellitus (NIDDM) and exhibits age-related hyperglycemia (Berdanier 1991). This study
assigned forty male weanling llHElcdb rats to foUl; c:~perimental diet groups within a 2x2
factorial design with deficient and adequate dietary chromium and copper. Several
glucose tolerance tests were perfonned throughout the study to analyze the state of
glucose tolerance and possible mineral depletion in these animals. After thirteen weeks on
AIN-93G recommended diets, the animals' weights had·plateaued, and they were switched
to a high fat diet containing 22% soybean oil to try to exacerbate the effects ofmineral
depletion upon glucose tolerance. After twenty-one weeks on the experimental diets, the
animals were killed. At necropsy, several serum and urine parameters related to
cardiovascular disease were analyzed. Analysis ofvariance, least squares means, and
Pearson correlation coefficents were used to determine statistical significance among the
treatment groups.
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Copper depletion significantly lowered baseline glucose within the chromium
depleted groups in the first glucose tolerance test and significantly increased total urine
creatinine in the second glucose tolerance test. Total urinary creatinine positively
correlated with current body weight during the first glucose tolerance test. At necropsy,
chromium depletion significantly increased liver, kidney, and spleen percent body weight.
Chromium depletion also significantly decreased non-esterified fatty acids (NEFA) and
blood urea nitrogen (BUN). Copper depletion significantly lowered total cholesterol at
necropsy.
Several parameters related to cardiovascular disease risk were positively correlated
to one another. Triglyceride was positively correlated with glucose and NEFA. Insulin
positively correlated with cholesterol, serum uric acid, fat mass, and 'final weight. NEFA
also positively correlated with glucose and fructosamine. Serum magnesium positively
correlated with serum uric acid. This set ofcorrelations includes interrelated parameters
pertinent to diabetes mellitus and cardiovascular disease. Lee et al. (1995) tenned this
relationship the Obesity-Insulin Resistance Syndrome, while Reaven (1988) coined the
term "Syndrome X" to describe this cluster of symptoms.
Regardless of the tenn used, several of these physiological abnonnalities which are
intertwined within diabetes mellitus and cardiovascular disease were significantly present
in the BHE/cdb rat within the dietary treatments ofdepleted and adequate chromium and
copper. These results indicate that mineral depletion ofchromium and copper may have a
significant effect upon cardiovascular disease risk in the BHE/cdb rat model.
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Test of NuD Hypotheses
The null hypotheses were tested based upon the data obtained in this study:
Ho 1. There will be no statistically significant effect ofdietary chromium on
selected factors related to cardiovascular disease risk in the BHElcdb rat.
Chromium depletion significantly increased liver, kidney, and spleen percent body
weight at necropsy. In addition, chromium depletion significantly decreased NEFA and
BUN at necropsy. Chromium depletion or adequacy did not have an effect upon the
remaining parameters analyzed in this study. Hypothesis one was rejected.
Ho 2. There will be no statistically significant effect of dietary copper on selected
factors related to cardiovascular disease risk in the BHFlcdb rat.
Copper depletion significantly increased total urine creatinine in the second
glucose tolerance test and significantly decreased total "Cholesterol at necropsy. Copper
depletion or adequacy did not significantly affect the remaining factors included in this
study, though. Hypothesis two was rejected.
Ho 3. There will be statistically significant interactions between dietary chromium
and copper affecting selected factors related to cardiovascular dieease risk in the BHE/cdb
rat.
A significant interaction did exist in the first glucose tolerance test during the
study. Copper depletion significantly lowered baseline glucose within the chromium
depleted groups in this test. There were no other significant interactions between dietary
chromium and copper in the remaining factors studied. Hypothesis three was rejected.
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Recommendations
To confirm the effect of depleted chromium and copper on factors related to
cardiovascular disease in the BHE/cdb rat, more studies are recommended. A confirmed
state of impaired glucose tolerance (IGT) or hyperinsulinemia should be present to
accurately assess the effects ofmineral depletion in many ofthe parameters selected for
this study in the BHE/cdb rat. As seen in the results ofthe glucose tolerance tests, this
glucose intolerant state may never have been reached in this study. The BHE/cdb rats
were not hyperinsulinemic at necropsy, either. In addition, the high fat diet was only
administered during the last eight weeks ofthe study. With the use ofa high fat diet in
BHE/cdb rats from weanling age for the duration ofa study, IGT and hyperinsulinemia
might be obtained more rapidly and cause more significant effects from mineral depletion
in the factors selected here. As laboratory facilities become available, other parameters
wilJ be measured to fully examine the effects of mineral depletion in the BHE/cdb rat.
These parameters include urine hydroxyproline, bone and tissue chromium and copper,
plasma fibrinogen, serum corticosterone and ceruloplasmin, and experimental diet
concentration ofchromium and copper.
The most elevated blood glucose was observed during the first glucose tolerance
test during the twelfth week. This observation could indicate that mineral depletion
effects are more significant during growth for this animal. Future studies using high fat,
mineral depleted diets with documentation of IGT and hyperinsulinemia are strongly
recommended within this animal model ofNIDDM.
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APPENDIX A
COMPOSITION OF INITIAL DIET
Ingredient
Casein
Cornstarch
Cellufil
Dextrose
Sucrose
Vitamin Mix l
Soybean Oil
Choline
L-Cysteine
Mineral Mix2
Amount (g)
200.0
150.0
50.0
379.5
100.0
10.0
70.0
2.5
3.0
35.0
Percentage
20.00%
15.00%
5.000,/0
37.95%
10.000,/0
1.00%
7.000,/0
0.25%
0.30%
3.50%
1 Vitamin mix formulated to meet the AIN-93G recommendations for
growing rats except for a five fold increase in Vitamin E, or 0.6 glkg diet mix.
2 Mineral mix formulated to meet the AIN-93G recommendations for
growing rats except for inadequate levels of chromium (0 glkg added to mineral
mix) and copper (0.03 g/kg mineral mix) as specified by the experimental design.
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COMPOSITION OF IDGH-FAT DIET
Ingredient Amount (g) Percentage
Casein 140.0 14.00%
Cornstarch 150.0 15.00%
Cellufil 50.0 5.00%
Dextrose 289.5 28.95%
Sucrose 100.0 10.00%
Vitamin Mix] 10.0 1.00%
Soybean Oil 220.0 22.00%
Choline 2.5 0.25%
L-Cysteine 3.0 0.30%
Mineral Mix2 35.0 3.50%
1 Vitamin mix formulated to meet the AIN-93G recommendations for
growing rats except a five fold increase in Vitamin E, or 0.6 g1kg diet mix.
2 Mineral mix formulated to meet the AIN-93G recommendations for
growing rats except for inadequate levels ofchromium (0 g1kg added to mineral
mix) and copper (0.03 g1kg mineral mix) as specified by the experimental design.
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DIET PREPARATION
Instructions for Mixing:
Step 1: Put on clean mineral free gloves
Step 2: In the small mixing bowl, combine the following ingredients one at a time:
1) Vitamin Mix
2) L-Cysteine
3) Choline
4) Casein (~ 1 cup)
5) Dextrose (~3 cups)
6) Sucrose
Step 3: Mix each ingredient thoroughly as they are added using your hand with mineral-
free gloves. (Make sure all small clumps are broken.)
Step 4: Use the large mixing bowl to combine the following ingredients. Again, add each
ingredient one at a time and use your hands to combine and break up any clumps.
1) Remainder ofDextrose
2) Remainder of Casein
3) Celufil
4) Cornstarch
Step 5: Add around 2 Tbsp. of oil and mix at a setting of"1" on the large mixer for 10-15
minutes (or until well mixed). Add the remainder of the oil and continue mixing.
Step 6: When the six ingredients in the small mixing bowl have been thoroughly combined
by hand, add about 1/2 Tbsp. of oil and mix at low speed (setting of"1") for 5-19
minutes or until well mixed. Next, add the Mineral Mix and stir with plastic
spoon. Continue mixing at a setting of"1" until the ingredients are completely
mixed.
Step 7: When the ingredients in each mixer appear to be ready, combine aU ingredients into
the large mixing bowl and set speed at "1.5" and mix for approximately 20
minutes.
Step 8: Place diet in a plastic bag, mark it accordingly and store it in the freezer.
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DIET PREPARATION
Instructions for Mixing:
Step 1: Put on clean mineral free gloves
Step 2: In the small mixing bowl, combine the following ingredients one at a time:
1) Vitamin Mix
2) L-Cysteine
3) Choline
4) Casein (~ 1 cup)
5) Dextrose (~ 3 cups)
6) Sucrose
Step 3: Mix each ingredient thorougWy as they are added using your hand with mineral-
free gloves. (Make sure all small clumps are broken.)
Step 4: Use the large mixing bowl to combine the following ingredients. Again, add each
ingredient one at a time and use your hands to combine and break up any clumps.
1) Remainder ofDextrose
2) Remainder ofCasein
3) . Celufil
4) Cornstarch
Step 5: Add around 2 Tbsp. of oil and mix at a setting of"1" on the large mixer for 10-15
minutes (or until well mixed). Add the remainder of the oil and continue mixing.
Step 6: When the six ingredients in the small mixing bowl have been thorougWy combined
by hand, add about 1/2 Tbsp. of oil and mix at low speed (setting of"1") for 5-19
minutes or until well mixed. Next, add the Mineral Mix and stir with plastic
spoon. Continue mixing at a setting of"1" until the ingredients are completely
mixed.
Step 7: When the ingredients in each mixer appear to be ready, combine all ingredients into
the large mixing bowl and set speed at "1.5" and mix for approximately 20
minutes.
Step 8: Place diet in a plastic bag, mark it accordingly and store it in the freezer.
106
APPENDIXD
XAN11IINE OXIDASE PROCEDURE
(Singh et aI., 1987)
Substrate Buffer: Total volwne = lOOrnL
Dissolve 0.1 361g hypoxanthine (lOmM, FW=136.lg/mole) in 70 mL 25rnM NaOH. Add 0.1300g
NaN3 (20mM, FW=65.01 g1rnole). Add 30 ML of 66.7 mM KH2P04. This solution should have
pH=7.9.
Reagent: Total volume = 1000mL
Dissolve 1.0974g (2mM, FW=548.7g1mole) ABTS (2,2'-azino-di(3-ethyl-benzthiozoline-6-
sulphonate) in a little 66.7 mM KfuP04. Add 2500 Wlites of horseradish peroxidase (POD) (2500
unitsIL). Dilute to lL with 66.7 mM KH2P04. This solution is stable for more than 2 months.
Uricase:
10 units/mg in 50% glucose
2M HCI04:
In a IL volwnetric flask, add 220 mL of concentrated HCI04 (9.1 M). Dilute to 1L with distilled
water.
PROCEDURE
I. Pipet 1 mL substrate buffer + 5uL uricase + 50 uL serwn into a centrifuge tube.
For blank: 1 mL (66.7mM KH2P04 with 20mM NaN3) +5uL uricase + 50uL serum into
a centrifuge tube. *Each subject will have a blank.
2. Incubate at 30°C for 10 minutes.
3. Add 1.0 mL reagent solution. Vortex.
4. Immediately add 1.0 mL of 2M HCI04. Vortex.
5. Centrifuge for 5 minutes at 3000 rpm.
6. Read A410nm against blank. Final reaction product is stable for 15 minutes.
Preparation of other reagents:
I. 25mM NaOH (FW=40g/mole): Dissolve O.IOOg NaOH in a little distilled water. Dilute
to 100mL.
2. 66.7mM KH2P04 (FW=136.1g/mole): Dissolve 9.0779g KH2P04 in a little distilled
water. Dilute to 1000 mL.
3. 66.7mM .KH2P04 with 20mM NaNJ (FW=65.01 glmole): Dissolve 0.1300g NaN3
in 100 mL 66.7mM KH2P04.
Calculation: Xanthine Oxidase activity (UnitslL) == A4lOnrn x 79.9
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